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The intermediate conductance calcium (Ca2+)-activated potassium (K+) channel (KCa3.1) is 
targeted to the basolateral membrane of polarised epithelial cells, and is also found in many non-
epithelial cell types. KCa3.1 performs several fundamental roles, including the promotion of 
transepithelial ion transport, and the maintenance of a homeostatic equilibrium inside cells. Thus, 
KCa3.1 is found in a wide range of tissues, from epithelial to neural, and is involved in several disease 
states. These disease states include sickle-cell anaemia, cardiac fibrosis, and diabetic nephropathy, 
and paint KCa3.1 as a potential target for novel disease therapies.  
In order to create these novel disease therapies, it is vital to understand how KCa3.1 is 
trafficked within the cell. Functionally, KCa3.1 is trafficked from the ER to the Golgi in a manner 
dependent on Rab1, and from the Golgi to the plasma membrane in a manner dependent on Rab8. 
Additionally, KCa3.1 trafficking has been shown to require a functional cytoskeleton, as well as the 
motor protein Myocin-Vc. One trafficking pathway which may traffic KCa3.1 is the Retromer 
pathway. This pathway involves multiple protein complexes, including the cargo recognition 
complex, and the WASH complex, as well as multiple individual sorting nexin proteins. If KCa3.1 is 
found to interact with components of the Retromer pathway, it could lead to new disease therapies. 
This project examined the role of three distinct sorting nexin protein; SNX1, SNX4, and SNX27, 
on the trafficking and basolateral membrane population of KCa3.1 in polarised epithelial cells. In 
order to do this, Fischer Rat Thyroid cells transfected to stably express a KCa3.1-BLAP (biotin ligase 
acceptor peptide) construct, were transfected with SNX1, 4, or 27 specific siRNA, then grown on 
filters in order to achieve polarity. This allowed for the apical and basolateral membrane populations 
of KCa3.1 to be independently assessed.  
Immunoblots were used to determine the extent to which transfections were successful. In 
cells where the transfection was successful, the basolateral membrane population of KCa3.1 was 
determined by immunoblots. Additionally, Ussing chamber experiments were utilised in order to 
explore the effects of transfections on the KCa3.1 current when stimulated by the KCa3.1 opener 1-
EBIO, or the KCa3.1 inhibitor clotrimazole.  
This project showed the first evidence of the endogenous expression of SNX1 and SNX27 in 
FRT cells, and confirmed expression of SNX4 in FRT cells, first discovered in the McDonald Lab. 
Following this demonstration, cells were transfected with 40 pM of either SNX1, SNX4, or SNX27 
siRNA. The transfection with SNX1 siRNA resulted in a 44 ± 8% decrease in SNX1 protein levels, 
however, showed no significant decrease in the basolateral membrane population of KCa3.1, nor in 
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the KCa3.1 sensitive current measured by Ussing chamber experiments was observed. The 
transfection with SNX4 showed a 62 ± 12% decrease in intracellular SNX4, however, similar to SNX1, 
a decrease in intracellular SNX4 did not appear to affect either the basolateral membrane population 
of KCa3.1, nor the KCa3.1 sensitive currents. Finally, the transfection of cells with SNX27 siRNA 
showed a 27 ± 4% decrease in the intracellular protein levels of SNX27. While knockdown of SNX27 
did not elicit a significant change in the basolateral membrane population of KCa3.1, it did suggest 
the possibility of KCa3.1 missorting to the apical membrane, as there was a trend towards a 
significant increase in the apical membrane population of KCa3.1 in the SNX27 knockdown cells 
compared to the control cells (p = 0.0818; n=4). These results appear to be consistent with the 
notion that KCa3.1 is not recycled in polarised epithelial cells, and suggest that KCa3.1 is not 
trafficked via the Retromer pathway. While KCa3.1 does not appear to be trafficked via the 
Retromer pathway, there are still unknown factors regarding the trafficking of KCa3.1 which need to 
be explored, such as why KCa3.1 appears to be recycled in migratory cells. It is important to fully 
comprehend the trafficking mechanisms surrounding KCa3.1 in order to develop novel effective 
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The tissues of animals can be separated into four distinct categories; connective tissue, 
muscular tissue, nervous tissue, and epithelial tissue. While each of these tissue categories are vital, 
epithelial tissue is perhaps the most significant, as this is the tissue used to isolate compartments of 
the body, and that conveys the epithelial barrier function which precisely controls the transport of 
solutes throughout the body (Simons & Fuller, 1985). Epithelial cells form epithelial tissue, and the 
individual epithelial cells themselves convey many important functions, including, selectively 
passaging macromolecules, through the use of channels and transporters, including solutes and ions, 
between body compartments separated by epithelial tissue. The maintenance of this selective 
passage is of paramount importance, as this selective passage of macromolecules maintains the 
homeostatic equilibrium of the body. 
In vivo, epithelial cells bind together to form a sheet of epithelial tissue, with individual cells 
connected by proteins found in the tripartite junctional complex (TJC), which also separates the cell 
membrane into two distinct regions, known as the apical (mucosal), and the basolateral (serosal) 
membranes (Farquhar & Palade, 1963; Tepass et al., 2001). The apical membrane domain is oriented 
to face the external environment, which includes the lumens of hollow organs such as the intestine, 
the kidney, and the lungs, whilst the basolateral membrane domain contacts both the basal lamina 
and adjacent epithelial cells (Simons & Fuller, 1985; Tepass et al., 2001; Apodaca et al., 2012). One of 
the main advantages of having two distinct membrane regions is to allow for cellular polarisation. 
Polarisation occurs when some membrane bound proteins are selectively trafficked to one domain. 
This is important as polarisation sets up solute gradients, allows for more controlled absorption and 
secretion of ions and solutes. The mechanisms behind these selective trafficking are discussed later, 
however, contributing factors to protein sorting include; protein synthesis in the endoplasmic 
reticulum (ER), posttranslational modifications in the ER and the Golgi apparatus, and cytoskeletal 
function (Ellgaard & Helenius, 2003).  
The main protein channel of interest for this project is the calcium activated potassium 
channel KCa3.1, which, in epithelial cells, is trafficked to the basolateral membrane (Bertuccio et al., 
2014; Farquhar et al., 2017). KCa3.1 functions primarily as a K+ channel to regulate the intracellular 
and extracellular K+ levels (Ishii et al., 1997) However, the exact mechanisms controlling the number 
of KCa3.1 channels in the membrane remains to be intensively studied. This being said, certain 
aspects of the KCa3.1 trafficking pathway have been determined, such as the proteins Rab1 and 
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Rab8 (Babbey et al., 2006; Zhang et al., 2009; Dong et al., 2010), which are responsible for the 
regulation of KCa3.1 transport from the ER to the cis-Golgi body, and from the trans-Golgi body to 
the plasma membrane respectively (Bertuccio et al., 2014). Secondary to KCa3.1, this project 
focusses on proteins involved in a novel protein recycling pathway known as the Retromer pathway. 
This pathway involves multiple protein complexes that facilitate recycling of membrane proteins 
back to the cell membrane after their endocytosis, the most prominent of which are the cargo 
selective complex, which selects and binds the Retromer cargo, and the WASH complex, which 
connects Retromer to the actin cytoskeleton, facilitating movement (Yang et al., 2005). While 
Retromer has been studied intensively by multiple groups since its discovery, nobody has studied the 
possibility of interactions between Retromer and KCa3.1 until now.  
1.2 Polarity in Epithelial cells 
Epithelial polarity allows for controlled absorption or secretion of ions and molecules across 
the epithelia, and is the mechanism responsible for basic physiological functions such as the 
absorption of nutrients and the secretion, and subsequent expulsion of waste. As mentioned 
previously, the apical membrane faces into the lumen of organs, such as the intestine, and faces into 
body cavities, however the basolateral domain can be described as two separate membrane 
domains, the lateral and the basal domains, despite not being physically separate, as the apical and 
the basolateral membranes are. The lateral membrane domain interacts with epithelial cells which 
are adjacent to the cell, and contains the TJC on the apical most area of the domain, which defines 
the border between the apical and the basolateral membranes. The basal membrane domain 
interacts with subjacent cells, or with the components of the basement membrane though 
interactions with integrin receptors and dystroglycans (Apodaca et al., 2012). Furthermore, the 
basolateral membrane contains a relatively high concentration of phosphatidylinositol-3, 4, 5-
triphosphate, which has been shown to regulate the formation of the basolateral membrane by 
acting as a target for basolaterally targeted proteins (Gassama-Diagne et al., 2006). When 
phosphatidylinositol-3, 4, 5-triphosphate was added to the apical membrane, basolateral proteins 
were found to target to the apical membrane, Additionally, this was found to not be due to 
disruption of the TJC, as the TJC was undisturbed by the addition of phosphatidylinositol-3, 4, 5-
triphosphate, and the epithelial monolayer did not become “leaky” which would signify disruption to 
the tight junctions (Gassama-Diagne et al., 2006). 
The main protein complex which is involved in creating a scenario where epithelial 
polarisation can exist is the TJC (Farquhar & Palade, 1963; Tepass et al., 2001), which acts on both 
the X, and Z-axes, forming a “ring” of membrane bound protein around the circumference of the 
cell. The TJC comprises of three individual elements; the zonula occludens (tight junction), the 
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zonula adherens (intermediate junction), and the macula adherens (desmosome) (Figure 1.1). The 
zonula occludens (ZO) is primarily characterised by the fusion of adjacent cell membranes, which 
results in the obliteration of the intercellular space. Furthermore, the ZO causes dense leaflets from 
the external plasma membrane of each cell to interact, forming a dense, single belt (Farquhar & 
Palade, 1963). Unlike the ZO, the zonula adherens (ZA) does not cause the elimination of the 
intercellular space, instead, the ZA is characterised by the presence of a small (~200 Ångströms (Å)) 
gap containing low density material. In some epithelia, the ZA forms a continuous belt, similar to the 
ZO, however this variable depending on the epithelia, and can be discontinuous (Farquhar & Palade, 
1963). Similar to the ZA, the macula adherens (MA) also contains an intercellular space, which is 
slightly larger than that of the ZA (~240Å). Furthermore, the MA contains a central disc of 
cytoplasmic plaques, and cytoplasmic fibrils which interact with the plaques in order to anchor the 
cells together (Farquhar & Palade, 1963). The 3 components of the TJC act together to prevent 
membrane bound proteins from migrating from one membrane domain to the other (Madara, 
1998). Furthermore, the TJC forms a semipermeable barrier, creating a secondary pathway for 
solutes to move, and controlling the paracellular transport of solutes (Figure 1.1) (Madara, 1998).  
1.3 Biosynthetic secretory pathway 
The biosynthetic secretory pathway is the cellular process behind the synthesis of cellular 
proteins. It is, therefore, important to understand the basics of this process when studying cellular 
protein function. Protein synthesis begins with the ribosomes in the cytosol, which decode 
Figure 1.1 – Diagram showing epithelial cells in vivo displaying the apical and basolateral membrane, the 
components of the TJC, and the different transport routes for solutes. The components of the TJC are colour 
coded as follows; red is the zonula occludens (tight junction), green is the zonula adherens (intermediate 
junction), gold is the macula adherens (desmosome), and black is the gap junction. Pilmore, Unpublished. 
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messenger RNA into amino acid sequences. For proteins to enter the secretory pathway, or for 
proteins that will be secreted or trafficked to the plasma membrane containing a hydrophobic signal 
sequence, the ribosomes move to the endoplasmic reticulum (ER), where the newly synthesised 
proteins undergo quality control (ERQC) (Rapoport et al., 1996). The ERQC acts to ensure that newly 
synthesised proteins are functioning correctly, and to prevent non-functional proteins from 
progressing in the trafficking pathway (Ellgaard & Helenius, 2003). Ineffective proteins are released 
into the cytoplasm, where they are degraded into their constituent amino acids through the 
ubiquitin-proteasome pathway (McCracken & Brodsky, 1996).  
Once proteins successfully navigate through the ERQC, they are trafficked towards the cis-
Golgi body via anterograde coat protein (COP) II vesicles (Barlowe et al., 1994). The COP II vesicles 
take proteins to the ER/cis-Golgi intermediate compartment, which acts to increase the 
concentration of proteins so that only a few vesicles are ultimately required to transport proteins 
(Figure 1.2) (Klumperman et al., 1998). Additionally, another type of COP vesicle, the COP I vesicle, 
also transports proteins around the Golgi and back to the ER, however, COP I largely traffics proteins 
Figure 1.2 – Schematic diagram of the biosynthetic secretory pathway in epithelial cells. Proteins are trafficked 
from the ER to the cis-Golgi body through two vesicle systems; COP II vesicles travel to the ER/cis-Golgi 
intermediate compartment (ERGIC), which then travels to the cis-Golgi body. Proteins containing an 
endoplasmic reticulum KDEL motif are trafficked back to the ER in COP I vesicles. COP I vesicles are also used to 
traffic proteins in a retrograde fashion between the stacks of the Golgi apparatus. Finally, proteins are released 
from the trans-Golgi body, and trafficked to the plasma membrane (shown here as the basolateral 
membrane), either directly or indirectly. Pilmore, Unpublished.  
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containing an ER retention motif consisting of Lysine, Aspartic acid, Glutamic acid, and Leucine 
(KDEL) (Figure 1.2) (Majoul et al., 2001). 
At the Golgi, proteins undergo further post translational modifications, which ensure that the 
proteins will be fully functional in the cell. There are two hypotheses as to how the Golgi apparatus 
traffics and matures proteins; the Vesicular Transport Model (VTM), and the Cisternal Maturation 
Model (CMM). The VTM proposes that the individual cisterna of the Golgi are static, and that 
proteins are trafficked between cisternae via COP I vesicles, receiving specific post translational 
modifications in each cisterna (Pfeffer, 2010). On the other hand, the CMM states that proteins 
enter the cisterna at the cis-Golgi, which then mature as the proteins inside receive post 
translational modifications (Figure 1.2). Furthermore, the CMM states that Golgi specific enzymes 
are trafficked retrogradely by COP I vesicles (Mironov et al., 2003), allowing for the individual 
cisterna to have a fluid enzymatic composition, compared to the static, but more specialised 
enzymatic composition seen in the VTM (Pfeffer, 2010). Ultimately, proteins exit the trans-Golgi 
body complete with post translational modifications which serve the dual functions of improving 
protein function, and facilitating protein trafficking through sorting signals (Wandinger-Ness et al., 
1990).  
1.3.1 Apical Trafficking Pathways 
In polarised epithelial cells, membrane proteins need to contain specific motifs in order to 
accurately traffic them to the appropriate membrane (Misek et al., 1984; Fuller et al., 1985). Apical 
sorting signals are often post translational modifications, most commonly N-linked or O-linked 
glycosylation (Scheiffele et al., 1995; Yeaman et al., 1997), both of which lead to protein missorting if 
not present. As these modifications are added in the Golgi apparatus, proteins are trafficked as soon 
as they exit the trans-Golgi body. In apical anterograde trafficking, proteins are sorted at the Golgi 
based on their affinities to interact with self-aggregated structures (Lafont et al., 1998; Ohkura et al., 
2014) comprised of cholesterols and glycosphyngolipids known as lipid rafts (Hakomori & Handa, 
2002; Wang & Silvius, 2003). The apically targeted proteins are sorted into vesicles, which then 
interact with lipid rafts, which act as the secondary sorting mechanism for apical transport vesicles 
(Brown et al., 1989; Lisanti et al., 1989; Kenworthy & Edidin, 1998). The main factor by which apical 
transport vesicles interact with lipid rafts is through the presence of glycosylphosphatidylinositol-
anchored proteins (GPI-APs). GPI-APs become incorporated into the lipid rafts as the rafts pick up 
the apically targeted proteins at the trans-Golgi body (Brown et al., 1989; Lisanti et al., 1989; 




While many apical proteins are trafficked through the use of lipid rafts, some proteins are not. 
These proteins still utilise apical transport vesicles, however these do not have the GPI-APs, and do 
not interact with the glycosphingolipids of the rafts. Irrespective of whether proteins utilise lipid 
rafts or not, apically targeted proteins either utilise certain endosomes, such as the apical early 
endosome, or the apical recycling endosome, or are targeted directly targeted to the apical 
membrane (Figure 1.3). Additionally, all apically targeted vesicles dock to the membrane to release 
their proteins into the plasma membrane by soluble NSF attachment protein receptor (SNARE) 
mediated fusion, with the proteins synaptosomal-associated protein (SNAP) 23, and two SNARE 
proteins; vesicle-associated membrane protein (VAMP) 7, and Syntaxin (STX) 3 (Lafont et al., 1999; 
Sharma et al., 2006), which are discussed further in section 1.3.2. 
1.3.2 Basolateral Trafficking Pathways  
Unlike apical sorting signals, basolateral sorting signals are often the result of specific amino 
acid sequences, rather than from post translational modifications. Furthermore, a large amount of 
heterogeneity is present between these proteins, meaning that basolaterally targeted proteins 
largely have differing amino acid basolateral targeting sequences, however there are some common 
Figure 1.3 – Basic anterograde trafficking routes in epithelia. Green shows apical protein sorting, including 
both the apical early (AEE) and recycling (ARE) endosomes, which can then traffic proteins either to the 
common recycling endosome (CRE), or to the apical membrane, where SNAP23 and either STX1A or STX3 
incorporate the proteins into the apical membrane. Additionally, in some polarised cells, apically targeted 
proteins can travel via the transcytotic pathway (Blue), where proteins are sent to the basolateral membrane, 
before being sent to the basolateral early endosome (BEE), then to the apical membrane. Orange shows 
basolateral protein sorting, including the BEE, which can traffic proteins either to the CRE or to the basolateral 
membrane, where SNAP23 and STX4 incorporate proteins into the basolateral membrane. Finally, proteins can 
be sent to a random membrane (Black), which achieves an asymmetric distribution through selective protein 
retention in the cell membrane through interactions with PDZ proteins. Pilmore, Unpublished. 
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motifs which have been identified. One of the main motifs involved in basolateral protein trafficking 
is the tyrosine (YXXØ) motifs, consisting of tyrosine (Y), two nonspecific amino acids (X), and a large 
hydrophobic residue (Ø) (Matter et al., 1992; Thomas et al., 1993; Sun et al., 2001). A second type of 
basolateral sorting signal are hydrophobic/dileucine (LL) motifs, which exist on the C-terminal 
domain (Miranda et al., 2001; Regeer & Markovich, 2004; Guezguez et al., 2006). Additionally, 
basolateral sorting signals and basolateral sorting machinery share common elements with 
endocytic sorting machineries (Rodriguez-Boulan & Musch, 2005; Deborde et al., 2008). 
Furthermore, it is not uncommon for basolateral proteins to have two sorting signals; both the low-
density lipoprotein receptor (LDLR) and aquaporin 4 (AQP4) have both a YXXØ motif and an element 
with an acidic residue cluster (Matter et al., 1992; Madrid et al., 2001). Similarly, the basolateral 
protein CD147 contains both a mono-leucine motif and an acidic residue cluster (Deora et al., 2004). 
There are two main mechanisms behind the basolateral trafficking of proteins; the use of 
adaptins and the exocyst complex. Adaptins contain heterotetrameric clathrin adaptor proteins, 
which recognise both the YXXØ and LL motifs through linking clathrin onto the membrane proteins 
(Yao et al., 2002; Doray et al., 2007). The adaptins AP-1 and AP-2 are two of the major components 
of clathrin coated vesicles, interacting predominantly with YXXØ and LL motifs, and serve different 
functions; AP-1 is involved in trans-Golgi body vesicles, while AP-2 is part of plasma membrane 
vesicles (Jackson et al., 2010; Robinson et al., 2010). Structural and biochemical experiments have 
shown that the YXXØ motif interacts with the µ subunit of AP-1 and AP-2 (Owen & Evans, 1998), 
while the LL domain has been suggested to have several interactions; the β subunit of AP-1 and AP-
2, the µ subunit of AP-1 and AP-2, the γ/δ hemicomplex of AP-1, and the α/δ hemicomplex of AP-2 
(Rodionov & Bakke, 1998; Bonifacino & Dell'Angelica, 1999; Geyer et al., 2002; Coleman et al., 2006; 
Doray et al., 2007).  
The other basolateral trafficking mechanism is the exocyst complex, consisting of eight 
subunits (Sec3, 5, 6, 8, 10, Exo70, and Exo 84), that acts to regulate the delivery of basolateral cell 
surface proteins (Lipschutz et al., 2000). The exocyst complex was discovered originally in the yeast 
Saccharomyces cerevisiae through biochemical and genetic experiments (Novick et al., 1980; 
TerBush & Novick, 1995; TerBush et al., 1996). The mammalian exocyst complex was first purified 
from rat brain, however it was further found in all the examined tissues (Hsu et al., 1996; Hsu et al., 
1998). Most of the exocyst subunits interact with multiple other exocyst subunits, although each 
individual subunit of the exocyst complex appears to have a unique function (Guo et al., 1999; 
Matern et al., 2001; Dong et al., 2005). Sec8 inhibition prevents the transport of the LDLR to the 
basolateral membrane, mutations in Sec5 and 6 hinder the trafficking of D-cadherin to the 
basolateral membrane, and overexpression of Sec10 reduces the transport of basolateral proteins 
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(Grindstaff et al., 1998; Lipschutz et al., 2000; Langevin et al., 2005). The exocyst is recruited to areas 
of membrane expansion and exocytosis, where it mediates vesicle tethering to the plasma 
membrane, at which point vesicle fusion through soluble N-ethylmaleimide-sensitive factor (NSF) 
protein receptor mediated membrane fusion can occur (discussed below) (Guo et al., 1999; Guo et 
al., 2000; Rivera-Molina & Toomre, 2013; Luo et al., 2014). In yeast, the exocyst protein Sec15 
interacts with Rab8 (Wu et al., 2005). If this interaction occurs between one of the mammalian 
exocyst subunits and Rab8 this could suggest a role of the exocyst complex in the trafficking of 
KCa3.1 to the basolateral membrane.  
1.3.3 Fusion of vesicles with the membrane 
Once proteins have been successfully trafficked out to the plasma membrane, the cell needs 
to insert the protein into the plasma membrane for it to function. This is made possible by 
specialised proteins which lower the energy needed to insert proteins into the membrane. One 
group of proteins with the primary function of aiding vesicle integration with the plasma membrane 
are the soluble N-ethylmaleimide-sensitive fusion protein-attachment receptors (SNAREs). SNAREs 
are classified into two categories; vesicle SNAREs (v-SNAREs), and target SNAREs (t-SNAREs) (Sollner 
et al., 1993). Both v-and t-SNAREs associate with the plasma membrane, however the v-SNARE 
reside on the outside of the vesicles, while the t-SNAREs are located on the plasma membrane, 
allowing for a SNARE complex to form, mediating the specific recognition and fusion of vesicles with 
membranes (Sollner et al., 1993).  
As with many protein groups, there are multiple v- and t-SNAREs. The v-SNAREs are known as 
vesicle-associated membrane proteins (VAMPs), and display polarity in polarised cells. This acts to 
stop any missorted vesicles from attaching to the incorrect membrane. VAMP7 is found on apically 
targeted vesicles, while VAMP3 is found specifically on basolaterally targeted membranes (Lafont et 
al., 1999; Procino et al., 2008). Unlike VAMP3 and VAMP7, another VAMP, VAMP8 does not show 
epithelial polarity, suggesting that VAMP8 is involved in exocytosis and recycling pathways (Wang et 
al., 2007). Similar to the polarity seen by the v-SNARE VAMP proteins, the t-SNARE proteins also 
exhibit epithelial polarity. STX (Syntaxin) 3 is primarily expressed on the apical membrane, and 
interacts with VAMP7 on apically targeted vesicles (Lafont et al., 1999), while STX 4 is expressed at 
the basolateral membrane, and interacts with VAMP3, found on basolaterally targeted vesicles 
(Procino et al., 2008). However, just as VAMP8 does not present polarity, there are two t-SNAREs not 
illustrating polarity in epithelial cells; STX 2 and Synaptosomal-associated protein 23 (SNAP23), 
which are both expressed at the apical and basolateral membranes (Fujita et al., 1998). In particular, 
SNAP23 interacts with both STX 3 and 4 to form t-SNARE complexes at the apical and the basolateral 
membranes respectively (Figure 1.3).  
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1.4 Families of Potassium Channels 
Whilst K+ channels share the ability to traffic K+ ions with a higher affinity than Na+ ions 
(Morais-Cabral et al., 2001), they can be separated out into four general families; voltage gated 
channels, inward rectifying channels, tandem pore channels, and calcium (Ca2+) activated channels 
(Jiang et al., 2002; MacKinnon, 2003). Ca2+ activated K+ (KCa) channels, which includes the channel 
KCa3.1, discussed in section 1.4.1, are activated directly or indirectly by the presence of intracellular 
Ca2+. The KCa channel family can be further subdivided into three categories, based on their 
conductance; big conductance (BK) channels, intermediate conductance (IK) channels, and small 
conductance (SK) channels. The SK and IK channels are both members of the KCNN gene family (Ishii 
et al., 1997; Joiner et al., 1997), therefore, both the IK and SK channels are relatively similar. Both 
the IK and SK channels are activated by Ca2+ as it binds to a calmodulin domain on the C-terminal 
complex (Xia et al., 1998; Fanger et al., 1999; Schumacher et al., 2001). Furthermore, both the IK and 
SK channels exhibit a relatively low conductance; IK has a conductance of ~20-45 pS, while SK is even 
lower, with a conductance of ~2-20 pS (Ishii et al., 1997; Joiner et al., 1997). For reference, the BK 
channel has a conductance of ~200 pS (Barrett et al., 1982). The similarities that exists between the 
IK and SK channels are due to them all being members of the KCNN gene family, with the IK channel 
(IK1/KCa3.1) exhibiting ~40% similarity at the amino acid level compared to the SK channels (SK1-
3/KCa2.1-3) (Ishii et al., 1997; Joiner et al., 1997).  
The SK channels were first cloned from the mammalian brain (Kohler et al., 1996), and were 
identified before KCa3.1 was identified (Ishii et al., 1997; Joiner et al., 1997). SK channels contain the 
Figure 1.4 – The KCa3.1 channel. This diagram shows the KCa3.1 channel, containing six transmembrane 
domains, labelled S1-S6. KCa3.1 also contains a calcium binding calmodulin domain on the C-terminus, and a 
pore forming loop between the 5th and 6th transmembrane domains. At the plasma membrane, four of the 
proteins shown here combine to form a heterotetrameric functional KCa3.1 channel. Pilmore, Unpublished. 
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traditional K+ selectivity pore in their pore loop, which is located between S5 and S6 (Kohler et al., 
1996). The trafficking of the SK channel KCa2.3 has been shown to be controlled by a number of 
factors, including the calmodulin domain used in channel activation (Lee et al., 2003). Additionally, it 
has been shown that the N-terminal domain, the proximal C-terminal domain, and the calmodulin 
domain are all vital to traffic KCa2.3 from the ER out to the Golgi body, and that the distal C-terminal 
domain contains motifs which are required for KCa2.3 to exit the Golgi body and enter transport 
vesicles (Roncarati et al., 2005).  
Importantly for this project, KCa2.3 has been shown to be recycled, which suggests that other 
members of the KCNN gene family may have also retained the ability for recycling. KCa2.3 has been 
shown to undergo membrane recycling, which is dependent on RME-1, Rab35, and an N-terminal 
domain (Gao et al., 2010; Lin et al., 2012). Additionally, KCa2.3 endocytosis has been shown to 
undergo caveolar trafficking, with endocytosis dependent on GTPases, and exocytosis depending on 
N-ethylmaleimide (NEM) (Lin et al., 2012), although the experiments performed by Lin and 
colleagues were in endothelial, rather than epithelial cells. While KCa2.3 has been shown to be 
recycled, current evidence suggests that KCa3.1 is not, instead, only undergoing a process of slow 
internalisation followed by degradation (Lin et al., 2012). Furthermore, under the timescale 
measured by Lin and colleagues (< 30 mins), KCa3.1 was found to not be trafficked from the 
basolateral membrane (Lin et al., 2012). While these results suggest that KCa3.1 is not recycled, a 
paper by Schwab and colleagues (Schwab et al., 2012) proposed that KCa3.1 is recycled in migratory 
cells. This team showed that KCa3.1 is subject to clathrin mediated endocytosis, and calculated that 
KCa3.1 should be internalised much faster than the 60-90 min half-life which is observed (Balut et 
al., 2010). This lead Schwab and collaborators to suggest their results were consistent with the 
notion of channel recycling, despite not producing data showing channel internalisation kinetics. 
1.4.1 KCa3.1 
In 1958, Gyorgi Gárdos was studying currents in erythrocytes when he observed that the 
addition of Ca2+ resulted in a stimulated electrical current (Gardos, 1958). It was further noted by 
Gardos that as Ca2+ increased, there was a resultant increase in K+ efflux. Although this Ca2+ sensitive 
K+ current was first observed in 1958, the current was not accurately shown to be that of KCa3.1 
until 2003 (Hoffman et al., 2003). While the intermediate conductance Ca2+ activated K+ channel is 
primarily referred to nowadays as KCa3.1, in the past it was referred to as IK1, IKCa4, and originally as 
SK4.  
The KCa3.1 channel consists of a tetrameric structure showing rotational symmetry around 
the channel pore, which, when constructed correctly, forms a voltage and time independent, ligand 
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binding channel. Each of the four subunits which make up KCa3.1 are comprised of 427 amino acids, 
arranged to form six transmembrane domains and a P loop between domains 5 and 6 (Figure 1.4) 
(Jiang et al., 2003; Klein et al., 2007). While it has been mentioned that KCa3.1 is activated by Ca2+, 
which binds to a calmodulin receptor on the C-terminal domain, KCa3.1 is also known to be 
activated by ATP, 1-EBIO, and DCEBIO (Devor et al, 1996; Joiner et al, 1997; Fanger et al, 1999; 
Gerlach et al., 2001). Furthermore, KCa3.1 has a number of inhibitors, namely charybdotoxin and 
clotrimazole (Devor et al., 1997; Ishii et al., 1997; Joiner et al., 1997).  
1.4.2 Trafficking of KCa3.1 
Much of KCa3.1 trafficking remains to be studied, however, there are certain aspects which 
have been deciphered. The majority of the knowledge regarding KCa3.1 trafficking is based on the 
anterograde KCa3.1 trafficking pathway. Recently, Bertuccio and colleagues (2014) examined the 
role of Rab1 and Rab8 in the trafficking of KCa3.1 to the basolateral membrane. Previously, the roles 
of both Rab1 and Rab8 in epithelial trafficking had been clearly defined; Rab1 regulates ER → cis-
Golgi apparatus trafficking (Zhang et al., 2009), while Rab8 regulates trans-Golgi → basolateral 
membrane trafficking (Chen et al., 1998). The role of both Rab1 and Rab8 in the trafficking of KCa3.1 
was discovered through dominant-negative mutations of Rab1 and Rab8, which resulted in a 
reduction of the membrane population of KCa3.1 at the basolateral membrane, demonstrating an 
essential role for both Rab1 and Rab8 in KCa3.1 trafficking. Additionally, it was shown that, following 
exit from the Golgi apparatus, KCa3.1 is not trafficked through either the transferrin receptor 
positive recycling endosomes, nor through RME-1, suggesting that KCa3.1 is directly trafficked to the 
basolateral membrane (Bertuccio et al., 2014). 
As mentioned above, there are conflicting studies regarding the possible recycling of KCa3.1; 
Schwab found that KCa3.1 appeared to be internalised in a manner consistent with channel recycling 
in migratory cells (Schwab et al., 2012), while Lin found that KCa3.1 was only subject to slow 
internalisation and degradation in aortic vessels (Lin et al., 2012). While Lin and colleagues did not 
find any evidence of KCa3.1 recycling, they did find evidence of KCa2.3 recycling (Lin et al., 2012). 
This suggest that other members of the KCNN gene family may be recycled, such as KCa3.1.  
Furthermore, the role of two further aspects have been established in KCa3.1 trafficking; the 
cytoskeleton and the motor protein myocin-Vc. Inhibiting either cytoskeletal activity or myocin-Vc 
activity each reduced targeting of KCa3.1 to the basolateral membrane, however it is unknown 
whether or not KCa3.1 is missorted to the apical membrane, or if it simply never reaches the 
membrane (Farquhar et al., 2017). In addition, Farquhar and colleagues (2017) stated that it is not 
understood the exact role that myocin-Vc plays in the trafficking of KCa3.1, and suggested that, it is 
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likely that myocin-Vc affects KCa3.1 trafficking after KCa3.1 leaves the Golgi apparatus, as both 
myocin-Vc and the cytoskeleton have been shown to interact with Rab8 (Chabrillat et al., 2005; 
Watanabe et al., 2008; Xu et al., 2009). Farquhar and collaborators (2017) proposed that, as myocin-
Vc has been shown to traffic cargo along the microtubules, it is possible that myocin-Vc allows 
KCa3.1 to be trafficked along the microtubule cytoskeleton of the cell (Jacobs et al., 2009).  
1.4.3 Clinical relevance of KCa3.1 
As KCa3.1 is present in a wide variety of tissues, it is able to play a role in a number of 
pathophysiological states. Under normal physiological conditions, KCa3.1 plays an important role in 
the homeostasis of both intracellular and extracellular K+, therefore, if this balance is disrupted, it 
can lead to serious pathophysiological conditions. As it stands, this makes KCa3.1 out to be an 
attractive target for disease therapy. However, in order to generate novel therapies, it is vital to 
obtain a more complete understanding of both KCa3.1 trafficking and KCa3.1 stimulation/inhibition, 
as different disease states alter KCa3.1 expression in different ways; some states increase the 
membrane population of KCa3.1, while some decrease it, and some disease states act to alter the 
open probability of KCa3.1. Current experimental data suggest that altering the membrane 
population of KCa3.1, thus “resetting” the membrane population of KCa3.1 back to physiological 
levels, could act as a compensatory mechanism to reduce the effects of certain disease states. 
1.4.4.1 Hereditary xerocytosis 
Recently, it has been reported that KCa3.1 plays a role in hereditary xerocytosis (HX), which is 
also known as dehydrated hereditary stomatocytosis. HX is an autosomal dominant disease, 
resulting in congenital haemolytic anaemia, and is clinically categorised by primary erythrocyte 
dehydration (Miller et al., 1971). This dehydration is the result of greatly increased K+ permeability in 
comparison to Na+ permeability, which results in the loss of KCl from the cells, leading to cellular 
water loss in order to maintain the osmotic equilibrium (Miller et al., 1971). There have been three 
mutations in the KCNN4 gene which codes for KCa3.1 which have been linked to HX; one mutation 
within the calmodulin binding domain, and the other two on the pore forming domain (Andolfo et 
al., 2013; Glogowska et al., 2015; Rapetti-Mauss et al., 2015). As the KCNN4 mutations which lead to 
HX ultimately increase KCa3.1 channel activity, it is believed that the increased K+ efflux from KCa3.1, 
leads to Cl- efflux, and subsequently, water exits the erythrocytes. This mechanism is similar to the 
erythrocyte dehydration seen in sickle cell anaemia (Lauf et al., 1992; Gibson et al., 1998), where 




1.4.4.2 Ulcerative colitis 
A second disease state involving KCa3.1 is the inflammatory bowel disease, ulcerative colitis 
(UC). In the human colon, the dominant driving force of water absorption is electrogenic Na+ ion 
transport (Greig et al., 2004). A decrease in the potential difference caused by the electrogenic Na+ 
transport is a trademark trait of inflammation in the mucosa, reflecting downregulation of apical Na+ 
channels (Amasheh et al., 2004). A further driving force in water absorption are basolateral K+ 
channels, such as KCa3.1 (Sandle et al., 1994). These channels determine the intracellular membrane 
potential, which is an important factor in Na+ channel activity, and therefore, water absorbance. In 
UC, unlike in HX, the basolateral membrane concentration of KCa3.1 has been found to be 
significantly reduced compared to healthy patients (Al-Hazza et al., 2012). This reduction in KCa3.1 
was sufficient to incur a 75% decrease in K+ ion flux, which lead to an impaired Na+ ion flux, and a 
subsequent reduction in the ability of affected cells to absorb water across the apical membrane (Al-
Hazza et al., 2012). While this does not specifically indicate that a reduction in KCa3.1 expression 
correlates directly to the pathophysiological symptoms of UC, KCa3.1 was suggested to be a 
potential target for disease therapy to treat the symptoms of UC. 
1.4.4.3 Autosomal dominant polycystic kidney disease 
Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic disorder affecting 
luminal organs such as the liver, pancreas, heart vesicles, and the brain; however ADPKD is best 
known for its pathophysiological renal effects (Dalgaard, 1957; Torres et al., 2007; Torres & Harris, 
2009). ADPKD can be caused by mutations in two individual genes, PKD1, which accounts for roughly 
85% of ADPKD cases, and PKD2, which accounts for the remaining 15% of cases (Harris, 2006). The 
PKD genes encode for the proteins polycystin-1 and polycystin-2, which are believed to interact to 
form a protein complex located in the primary cilia of epithelial cells, and has been suggested to 
facilitate Ca2+ influx through mechanosensation derived from fluid movement (Qian et al., 1997; 
Yoder et al., 2002).  
1.4.4.4 Sickle cell anaemia 
Sickle cell anaemia (SCA) is a genetic disorder affecting the haemoglobin protein in the 
erythrocytes, where a single amino acid substitution allowing for haemoglobin proteins to adhere to 
each other under acidic conditions, such as in low oxygen, high carbon dioxide conditions (Nagel & 
Lawrence, 1991). Under physiological conditions, the intracellular cation homeostasis in erythrocytes 
is maintained by the active movement of Na+ and K+ ions by the Na+/K+-ATPase channel, and low 
passive ion permeability (Joyce, 1958). However, in patients with SCA, the passive cation 
permeability is substantially higher, causing erythrocytes to shrink, elevating the relative 
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concentration of the aforementioned mutated haemoglobin (HbS). Furthermore, as the time 
required for haemoglobin polymerisation is inversely proportional to the concentration of HbS to the 
power of between 30-50 ([HbS]30-50), even small amounts of cell shrinkage severely increase the 
likelihood of HbS polymerisation (Eaton & Hofrichter, 1987).  
There are three main transport systems involved in erythrocyte dehydration; increased 
conduction of positive ions into the deoxygenated erythrocytes, the K+-Cl- cotransporter, and KCa3.1 
(Lew & Bookchin, 2005). Under deoxygenation, Ca2+ enters the cell (Rhoda et al., 1990), which 
activates the KCa3.1 channel, and in turn causes K+ and Cl- efflux through the both KCa3.1 and the K+-
Cl- cotransporter, leading to water loss (Lauf et al., 1992; Gibson et al., 1998). Additional studies 
have shown that hydration of erythrocytes can be increased through the use of KCa3.1 inhibitors, 
which reduce K+ efflux, therefore reducing Cl- efflux and reducing water loss (Brugnara et al., 1993; 
De Franceschi et al., 1994).  
1.4.4.5 Fluid secretion 
As discussed above, KCa3.1 is believed to be involved in the dehydration of erythrocytes under 
deoxygenated conditions, however, KCa3.1 also plays a role in fluid secretions elsewhere in the 
body. Fluid secretion as a result of Cl- efflux relies strongly on the activity of basolateral proteins in 
order to generate a sufficient electrochemical gradient. This gradient is generated in a two-step 
process; firstly, Na +/K+-ATPase uses primary active transport to export Na+ out of the cell against the 
concentration gradient, and secondly the Na+/K+/2Cl- cotransporter (NKCC) uses secondary active 
transport to import K+ and Cl- into the cell, driven by Na+ efflux. (Aleksandrov & Riordan, 1998; Trinh 
et al., 2008). KCa3.1 then allows for K+ efflux, preventing build-up of K+ from NKCC, and maintaining 
the K+ concentrations of both the extracellular and intracellular fluids, allowing for Na+/K+/ATPase to 
function optimally. As K+ efflux occurs, water is drawn out of cells in order to keep the osmotic 
homeostasis balanced, therefore, if more K+ occurs, due to increased KCa3.1, cells will have 
increased fluid secretion.  
KCa3.1 is also able to inhibit fluid secretion, for example, in the stomach, where parietal cells 
rely on K+ secretion through the H+/K+-ATPase channel (Vallon et al., 2005). Upon the activation of 
KCa3.1 in the stomach, K+ is able to exit cells on the basolateral side, which leads to a decrease in K+ 
efflux at the apical membrane, and inhibiting fluid secretion (Rotte et al., 2011). This was observed 
when DC-EBIO, a potent KCa3.1 activator, elicited a decrease in gastric secretions, an effect 
attenuated upon the addition of KCa3.1 inhibitor TRAM-34 (Rotte et al., 2011).  
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1.4.4.6 Cardiac fibrosis 
Fibrosis is the process of scarring, characterised by the accumulation of fibroblasts, resulting in 
the excess accumulation of the extracellular matrix, distorting the physiological architecture, and 
function of tissue. Cardiac fibrosis in particular, is a contributing factor in many cardiac diseases 
(Weber, 2000), and the contribution fibrogenesis plays in the impairment of cardiac function 
increasingly more recognised (Espira & Czubryt, 2009). Fibrosis itself can manifest in two forms; 
reactive interstitial fibrosis, or replacement fibrosis (Anderson et al., 1979). It is believed that left 
ventricular pressure overload leads to reactive interstitial fibrosis, which manifests into replacement 
fibrosis without the loss of cardiomyocytes (Isoyama & Nitta-Komatsubara, 2002). Acute myocardial 
infarction, on the other hand, results in myocardial cell death, and a state of replacement fibrosis 
(Hasenfuss, 1998).  
Furthermore, the onset of cardiac fibrosis has been suggested to be the result of an imbalance 
between the synthesis of collagen in the heart, and the degradation of the myocardium (Banerjee et 
al., 2006). Interestingly, KCa3.1 has been demonstrated to have a role in both the rate of collagen 
secretion, and the rate of cardiac fibroblast proliferation (Wang et al., 2013a; Zhao et al., 2015). 
Zhao and associates (2015) showed that inhibiting KCa3.1 with TRAM-34 in pressure overloaded rats, 
exhibited a significant reduction in cardiac fibrosis, shown through a decrease in both angiotensin II 
and in overall myocardial inflammation. These results therefore suggest that KCa3.1 may be a novel 
target for cardiac fibrosis therapy in humans, particularly in cases of reactive interstitial fibrosis.  
1.4.4.7 Diabetic nephropathy 
Diabetic nephropathy (DN), also known as diabetic kidney disease, is amongst the most 
prevalent, and dire long-term complications faced by diabetic patients, affecting between 30-40% of 
diabetes mellitus patients (Gross et al., 2005). DN is caused by angiopathy of the glomerular 
capillaries, resulting in a progressive pathological renal condition (Kanwar et al., 2008). Additionally, 
DN is the leading cause of end-stage renal disease in the United States of America, and is a lead 
contributing factor towards diabetic morbidity and mortality across the globe (USRD, 2009).  
One of the predominant conditions relating to DN is interstitial fibroblast activation; these 
fibroblasts rapidly proliferate, activating myofibroblasts in the process, leading to a marked increase 
in deposition of extracellular matrix into the renal interstitial space (Qi et al., 2006). As with cardiac 
fibrosis, discussed above, KCa3.1 has been known to be in fibroblasts since 1999, when it was cloned 
from fibroblast cells (Pena & Rane, 1999). Moreover, activated fibroblasts treated with TRAM-34 
have shown to have significantly reduced proliferation, suggesting that KCa3.1 may be a potential 
target for treating the fibrosis stemming from DN in patients (Grgic et al., 2009).  
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1.4.4.8 KCa3.1 in the neural system 
While the focus of KCa3.1 in disease thus far has revolved around cardiac and epithelial 
tissues, it has been shown, through immunolabelling, that KCa3.1 is expressed in all major neuronal 
cell types; including in the cingulate and motor cortices, cortical and subcortical neuronal regions, 
and the olfactory bulb (Turner et al., 2015). Additionally, KCa3.1 has been located in the spinal cord, 
where it plays a role in fluid secretion in ependymal cells, and in the dorsal root ganglion cells 
(Boettger et al., 2002; Bahia et al., 2005; Chen et al., 2015). Finally, KCa3.1 portrays an important 
role in the proliferation and migration of neuronal cells, such as endothelial cells and neuroblasts 
(Yamazaki et al., 2006; Turner & Sontheimer, 2014), and in the regulation of neuronal input to 
cerebellar Purkinje cells (Engbers et al., 2012).  
1.4.4.9 Alzheimer’s Disease 
Alzheimer’s disease (AD), is an irreversible, neurodegenerative disorder which progresses to 
slowly abolish patients’ cognitive ability. One of the lead factors contributing to AD is age; the 
incidence of AD is believed to double every 5 years after 65 years of age (Hirtz et al., 2007). One 
protein involved in the pathophysiology of Alzheimer’s disease is the amyloid-β protein (Aβ), which 
is a hydrophobic protein, which self-aggregates into amyloid fibrils, and deposits as amyloid plaques, 
which are a hallmark of AD. The Aβ aggregates which form then induce microglial activation, which 
clears the Aβ aggregates, but directly induces neurotoxicity through the release of inflammatory 
mediators in the process. (El Khoury et al., 2007; Cameron & Landreth, 2010). Aβ proteins are also 
expressed as oligomers (AβO), which also induce microglial activation (Maezawa et al., 2011). It was 
found that use of TRAM-34, a KCa3.1 inhibitor, amended the neurotoxicity caused by AβO induced 
microglial activation by controlling Ca2+ entry, preventing oxidative burst (Maezawa et al., 2011; 
Maezawa et al., 2012). Additionally, KCa3.1 blockade has been shown to be a target for another 
neural glial cell, astrocytes, which are also activated by Aβ accumulation (Wei et al., 2016) (Yi et al., 
2016). Together, these results suggest that KCa3.1 could be an effective target to prevent or 
diminish the neurodegradation which occurs upon Aβ accumulation.  
1.5 The Retromer pathway 
The retromer pathway is a trafficking pathway, which is believed to be involved in the 
recycling and degradation of plasma membrane proteins, and in the regulation of endosome to 
trans-Golgi body trafficking (Arighi et al., 2004; Temkin et al., 2011). Retromer was first observed in 
yeast (Seaman et al., 1998), where it was observed to be essential in the process of retrieving the 
yeast retromer protein receptor VPS10p (vacuolar protein sorting 10 protein) from the endosome to 
the Golgi.  VPS10p is a transmembrane sorting receptor which shuttles between endosomes and the 
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trans-Golgi body (Seaman et al., 1997). In yeast, the retromer complex consists of two sub-
complexes; the VPS26, 29, 35 trimer, or the cargo recognition complex (CRC) (shown in Figure 1.5), 
and the VPS17p-VPS5p heterodimer (Horazdovsky et al., 1997; Seaman et al., 1998). While the CRC 
has been highly conserved between species, the genes encoding for VPS17p and VPS5p have evolved 
to form four proteins, rather than two, which allows for a greater number of combinations of 
heterodimers to form. In mammals, these proteins are sorting nexin (SNX) 1, SNX2, SNX5, and SNX6, 
and these sorting nexin proteins all contain a Bin/Amphiphysin/Rvs (BAR) domain, helping to 
promote membrane curvature (Carlton et al., 2004). Like in yeast, these proteins still form dimers, 
however only specific combinations occur; either SNX1 or SNX2 are able to form a dimer with either 
SNX5 or SNX6 (Rojas et al., 2007).  
While the mammalian Retromer complex is largely homologous to the yeast Retromer 
complex in function (Arighi et al., 2004), the mammalian Retromer complex also regulates the 
transport of the mammalian homologue of the yeast protein VPS10p, sortilin (Mari et al., 2008; 
Fjorback et al., 2012). Recently, Retromer was found to play a role in the recycling of proteins from 
the early endosome to the plasma membrane (Chen et al., 2010). Retromer further uses a range of 
proteins in order to selectively recycle membrane proteins; for example, the beta-2-adrenergic 
receptor (β2AR) is recycled when the CRC containing the β2AR interacts with SNX27 (Temkin et al., 
2011). Retromer is therefore recognised as a critical regulator of many export pathways from 
endosomes (Pocha et al., 2011).  
Figure 1.5 – The Retromer complex. This diagram of the Retromer complex shows the cargo recognition 
complex (CRC), consisting of VPS26, 29, and 35, the WASH complex, consisting of CCDC53, WASH1, Fam21, 
SWIP, and Strumpellin, the SNX-BAR dimer, and SNX27, which is able to interact with both the WASH complex 
and the CRC. The green links show how proteins are able to interact with each other. Pilmore, Unpublished. 
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1.5.1 Structure of the cargo recognition complex 
The CRC is a complex consisting of three vacuolar protein sorting-associated (VPS) proteins; 
VPS26, VPS29, and VPS35, which form a heterotrimer in a 1:1:1 ratio (Figure 1.5) (Norwood et al., 
2011). While certain areas of the structure of VPS35 remains to be studied, it is known that VPS35 is 
a 796 amino acid long protein containing a curved surface with six helices and a series of 
hydrophobic grooves separated by ridges, believed to function as a binding site (Nothwehr et al., 
1999). Additionally, the N-terminus of VPS35 contains a Proline, Arginine, Leucine, Tyrosine, Leucine 
(PRLYL) motif, which interacts with VPS26 (Reddy & Seaman, 2001; Zhao et al., 2007), and the C-
terminus of VPS35 contains an α-solenoid fold which binds with VPS29 (Collins et al., 2005). These C- 
and N-terminal domains allow for VPS35 to function as the central scaffolding for the CRC (Hierro et 
al., 2007).  
The second protein of the CRC is VPS29, which is the smallest protein in the CRC, and 
associates with the concave face of the C-terminus of VPS35 (Hierro et al., 2007). VPS29 also utilises 
conserved residues to interact with the α-solenoid fold on the VPS35 C-terminus (Collins et al., 
2005). The final protein in the CRC is VPS26, a protein with three known isoforms; VPS26A, VPS26B, 
and Down’s syndrome critical region 3 (DSCR3). VPS26A was the first one of the three whose 
structure has been analysed, consisting of two sets of two antiparallel β sheets, connected together 
by a flexible linkage, and by a polar core (Shi et al., 2006). VPS26B has a very similar structure to 
VPS26A, including an identical binding motif to the A isoform, allowing for both isoforms to compete 
in binding to VPS35 (Collins et al., 2008). The final isoform of VPS26 is DSCR3, which remains to have 
its structure studied in depth, although it is believed to be a smaller size than either VPS26A or B 
(Collins et al., 2008). 
1.5.2 The WASH complex 
The Wiskott-Aldrich syndrome protein and SCAR Homologue (WASH) complex is an Arp2/3 
activating protein located on the endosomal surface. Arp2/3 is a seven-subunit complex which is 
both a component and regulatory factor of the actin cytoskeleton (Machesky et al., 1999; Marchand 
et al., 2001; Kelly et al., 2006) (Figure 1.5). As the WASH complex activates Arp2/3, WASH is an 
integral part of the Retromer pathway, allowing for the formation of branched actin filaments. The 
mammalian WASH complex consists of five separate subunits, which function as one obligate 
multiprotein complex; WASH1, Strumpellin, SWIP, CCDC53, and Fam21 (Derivery et al., 2009; Gomez 
et al., 2012). While these components of WASH are highly conserved across eukaryotes, they are 
absent in yeast (Derivery & Gautreau, 2010).  
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WASH is required for Retromer-mediated trafficking, and the CRC recruits the WASH complex 
into endosomes through multiple LFa motif interactions between VPS35 of the CRC, and Fam21 
(Family with sequence similarity 21) of WASH (Harbour et al., 2010; Harbour et al., 2012). 
Furthermore, these interactions require a fully functional CRC; Fam21 has been shown to only 
interact with VPS35 when VPS35 has formed an interaction with VPS29, suggesting that this 
interaction causes a conformational shift to allow for the Fam21-VPS35 interaction to establish 
(Helfer et al., 2013). The WASH complex has been shown to direct cargo in multiple directions; 
WASH is required to recycle the β2AR from the early endosome to the plasma membrane (Temkin et 
al., 2011), and to transport the mannose-6-phosphate receptor (CI-MPR) from the early endosome 
 to the trans-Golgi body (Gomez & Billadeau, 2009). Additionally, WASH has been shown to 
be responsible for the endosomal sorting of the LDLR (Bartuzi et al., 2016), which is trafficked to the 
basolateral membrane by the exocyst complex (Grindstaff et al., 1998). This interaction could signify 
the ability for WASH to traffic other exocyst trafficked proteins.  
The largest identified protein of the WASH complex, and a fairly unique member, is Fam21 (Jia 
et al., 2010), which has a notably long 1100 amino acid tail containing many features, amongst which 
are 21 LFa motifs (Jia et al., 2012). These LFa motifs are the way in which Fam21 interacts with 
VPS35; it is believed that the LFa motifs play a crucial role in the detection of the CRC density at the 
plasma membrane, further allowing for WASH recruitment coordination and the subsequent actin 
polymerisation which drives vesicle movement (Jia et al., 2012). While the interaction formed with 
VPS35 is perhaps the most notable formed by Fam21, Fam21 is capable of interacting with multiple 
proteins, linking the WASH complex with multiple proteins at the same time. Another notable 
interaction formed by Fam21 is with SNX27, which establishes that SNX27 mediated cargo is 
incorrectly trafficked if the interaction between SNX27 and Fam21 has not formed (Lee et al., 2016). 
Lee and collaborators (2016) also showed that this cargo is misstrafficked in different ways 
depending on if SNX27 or Fam21 are missing; if Fam21 is omitted, the cargo is missorted to the 
trans-Golgi body, whereas if SNX27 is absent, the cargo is sent to the lysosome for degradation (Lee 
et al., 2016). The globular head of Fam21 is also used for interactions; binding to both WASH1 of the 
WASH complex, and to SNX1/2, which further interact with the cargo in the CRC (Gomez & Billadeau, 
2009).  
1.5.3 Sorting nexins 
Sorting nexins (SNX) are a family of proteins with 33 unique members identified in mammals; 
although more members are apparent in other organisms such as yeast (Cullen, 2008). The members 
of the SNX protein family are characterised by the presence of a Phox (PX) domain (Teasdale & 
Collins, 2012), which interact with phosphatidylinositol-3-monophosphate (PtdIns3p) enriched 
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elements of the early endocytic network (Seet & Hong, 2006). Other domains possessed by SNX 
proteins, including SNX1, include the BAR domain, which consists of 3 α-domains, together forming a 
rigid curved structure(Carlton et al., 2004; Peter et al., 2004). This curved BAR domain has been 
hypothesised to bind optimally to the curvature of membranes, providing the ability to drive 
membrane curvature, leading to vesicle formation and stabilizing the highly curved membranes 
found in vesicles (Zimmerberg & McLaughlin, 2004; Frost et al., 2008).  
1.5.3.1 Sorting nexin 1 
SNX1, along with SNX2 are the mammalian orthologs of the yeast protein VPS5p, which forms 
an interaction with the VPS17p, who’s mammalian orthologs are SNX5 and SNX6 (Carlton et al., 
2005; Griffin et al., 2005; Rojas et al., 2007; Wassmer et al., 2009). Structurally, all of SNX1, 2, 5, and 
6 contain not only the characteristic PX domain of sorting nexins, but also a BAR domain. Along with 
PtdIns3P, SNX1 also interacts with phosphatidylinositol-3,5-biphosphate (Ptd (3,5) P2). This is the 
interaction required for SNX1 to target the highly-curved subdomains of the early endosome 
(Carlton et al., 2004). Due to the role SNX1 plays in the early endosome, it is also one of the defining 
features of the endosome to trans-Golgi network (TGN) transport carrier (ETC) (Bujny et al., 2007) 
(Figure 1.6).  
In the early endosome, SNX1 and another sorting nexin, SNX4, both form sorting tubules, 
however, these tubules are structurally distinct, and sort specific proteins to specific locations (Traer 
et al., 2007). The exact process behind how these sorting nexins form such distinct tubules remains 
to be uncovered, however variations in the affinity and specificity towards different 
phosphoinositides appears to be a contributing factor towards the formation of these highly-
specified sorting tubules (Carlton et al., 2004; Traer et al., 2007). Another factor which may 
contribute to the highly-specified tubules is that sorting nexins may form higher order complexes, 
which can specifically exclude other sorting nexins with similar functions (Carlton et al., 2004). It has 
also been suggested that sorting nexins such as SNX3 are able to utilise the transport structures 
created by sorting nexins like SNX1 and SNX4 in order to transport their cargo, as they are unable to 
synthesise transport structures (Strochlic et al., 2007).  
In epithelia, the RNA interference of SNX1 expression lead to defective Retromer mediated 
sorting, however similar experiments with SNX2 have failed thus far to outline a relationship 
between the two sorting nexins (Carlton et al., 2005; Rojas et al., 2007). SNX1 has been shown to 
interact with both SNX5 and SNX6, and the suppression of either SNX5 or SNX6 leading to a 
significant loss in the stabilisation of SNX1, further leading to a decrease in SNX1 expression 
(Wassmer et al., 2007). This suggests that the SNX-BAR heterodimers formed by SNX1/2 and SNX5/6 
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act together in order to generate an early endosomal tubular subdomain, allowing for the docking of 
the CRC.  
1.5.3.2 Sorting nexin 4 
Aside from SNX1, 2, 5, and 6, there is another SNX protein with a BAR domain; SNX4 (Traer et 
al., 2007). In yeast, the proteins SNX4, SNX41, and SNX42 act alongside the yeast proteins VPS5 and 
VPS17. While SNX4 in yeast forms a complex with SNX41 and SNX42, it is unknown if this complex is 
conserved at all in mammals, or if SNX41 or 42 have mammalian orthologues at all. The mammalian 
ortholog of yeast SNX4 acts in a similar way to SNX1, 2, 5, and 6, by creating transport tubules from 
the early endosome (Traer et al., 2007), although it is unknown if SNX4 plays a role in the tubular 
endosomal network (TEN) in the same way that SNX1 does. It is known that suppression of SNX4 
leads to the missorting of the transferrin receptor (TfnR) into the lysosomal degradation pathway, 
however, it is unknown if this missorting is due to the structural integrity of the TEN being affected, 
or if TfnR is trafficked through an intact TEN (Traer et al., 2007). 
Mammalian SNX4 does not appear to interact directly with TfnR, unlike in yeast, where a 
direct interaction occurs (Traer et al., 2007). It has been suggested that SNX4 interacts with another 
protein, reggie-1, which itself interacts with TfnR (Solis et al., 2013). An alternate hypothesis is that 
SNX4 regulates TfnR through the process of geometry based sorting; which proposes that the bulk 
Figure 1.6 – The early endosome. Clathrin coated vesicles bind to the surface of the early endosome and to 
the early endocytic sorting tubules. Tubules also protrude from the early endosome in order to sort proteins in 
vesicles. The red bands show the tubules formed by the SNX1/2-SNX5/6 heterodimer, which creates the 
endosome to TGN transport carriers (ETC). The green bands show the tubules formed by SNX4, which create 
the tubular endosomal network (TEN). The blue bands show SNX27, which utilises tubules in order to recycle 
proteins such as the β2AR back to the plasma membrane. The early endosome also traffics proteins to both 




flow of membrane exiting the early endosome does so through membrane tubules with a narrow 
diameter, similar to those created by SNX4 (Cohen & Pintavirooj, 2004). This allows for any protein 
lacking a sorting sequence which leaves the membrane by bulk flow, like TfnR, to be indirectly sorted 
by SNX4 (Traer et al., 2007). There is also evidence that SNX4 may be linked to molecular motors; as 
SNX4 interacts with the (-) end of the cytoskeletal motor protein dynein (Traer et al., 2007). This 
interaction is an important factor allowing for long range transport of SNX4 mediated cargo, such as 
TfnR-enriched domains. This long-range transport extends from simply occurring along early 
endosomal sorting tubules, as SNX4 cargo can be trafficked from the early endosome to the 
juxtanuclear endocytic recycling compartment. Dynein may also be used to assist membrane 
tabulation and membrane fission in SNX4 mediated transport (Day et al., 2015).  
1.5.3.3 Sorting nexin 27 
SNX27 is a unique sorting nexin in that it is the only sorting nexin currently known to contain a 
PDZ (post synaptic density protein 95, Drosophila disc large tumour suppressor 1, zonula occludens 
1) domain (Kajii et al., 2003). PDZ domains are commonly found in signalling proteins amongst 
kingdoms of life, including animals, and play critical roles in anchoring membrane bound receptor 
proteins to their cytoskeletal components (Ponting, 1997; Li et al., 2009). This PDZ domain is vital for 
the function of SNX27, as it allows for multiple proteins interactions to form, including interactions 
with ZO-2, a component of the tight junction (Zimmerman et al., 2013). PDZ domains are amongst 
the most prevalent protein-protein interaction scaffoldings found in trafficking and signalling 
proteins (Zhang & Wang, 2003). Among PDZ domains, there are two subcategories; canonical 
domains, which have a conserved cavity recognising different PDZ binding motifs, and noncanonical 
domains, which promote protein interactions with specific protein partners, involving protrusions 
from the core PDZ folds (Zhang & Wang, 2003). 
SNX27 itself utilises both the canonical and the non-canonical isoforms of PDZ domain in order 
to simultaneously interact with type1 PDZ ligands, and with the CRC through interactions with VPS26 
(Gallon et al., 2014). These unique interactions allow for SNX27 to act as a cargo adaptor protein for 
Retromer-mediated transport of endosomes to the cell surface (Lauffer et al., 2010; Temkin et al., 
2011; Steinberg et al., 2013; Gallon et al., 2014). These SNX27 cargoes include the β2AR (Lauffer et 
al., 2010), NMDA receptors (Wang et al., 2013b), and ion channels such as the basolaterally 
trafficked sodium-hydrogen exchanger 3 (NHE3) (Lunn et al., 2007; Balana et al., 2011; Singh et al., 
2015).  
Furthermore, SNX27 interacts with Fam21 of the WASH complex (Figure 1.5), through a direct 
interaction with the FERM (4.1 protein, ezrin, radixin, moesin) domain on the N-terminus of Fam21 
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(Lee et al., 2016). FERM domains are widespread domains specialised in the localisation of proteins 
to the plasma membrane, and are located in a number of proteins involved in both cytoskeletal 
movement and the plasma membrane (Chishti et al., 1998; Pearson et al., 2000). This interaction is 
critical for the correct trafficking of the β2AR, and for NHE3. As mentioned previously, if SNX27 is not 
present in the cell, the SNX27 mediated cargo is sent to degradation in the lysosome, whereas if 
Fam21 is not present, the SNX27 mediated cargo is sent to the trans-Golgi body (Lee et al., 2016). 
The current array of evidence suggests that Retromer is largely involved in recycling of proteins from 
the plasma membrane to the trans-Golgi network, or to the plasma membrane from the early 
endosome. Retromer is also believed to play a role in protein degradation. Despite the array of data 
surrounding Retromer, little is known about how, if at all, KCa3.1 interacts with Retromer, leading to 






1. To determine the effects of SNX1, SNX4, and SNX27 knockdown on the 
protein levels of SNX1, SNX4, and SNX27 in Fischer Rat Thyroid cells stably transfected 
with KCa3.1 (FRT-KCa3.1-BLAP cells). 
2. To determine if SNX1, SNX4, or SNX27 alter the trafficking of the KCa3.1 
channel to the basolateral membrane of polarised epithelial FRT-KCa3.1-BLAP cells.  
3. To assess any changes in the functional expression of KCa3.1 when any of 
SNX1, SNX4, or SNX27 are knocked down in polarised FRT-KCa3.1-BLAP cells through the 
use of Ussing chamber experiments. 
2.2 Hypotheses 
1. I hypothesise that knocking down SNX1, SNX4, or SNX27 will result in a 
decrease of the protein levels of SNX1, SNX4, or SNX27 in Fischer Rat Thyroid cells 
stably transfected with KCa3.1. 
2. I hypothesise that knocking down SNX1, SNX4, or SNX27 will decrease the 
membrane population of KCa3.1 at the basolateral membrane of polarised epithelial 
FRT-KCa3.1-BLAP cells. 
3. I hypothesise that the function of the KCa3.1 channel of KCa3.1 will be 






3.1 Cell models 
In this project, immortalised cell lines were used as a model in order to demonstrate the effect 
of Retromer disruption on the population of KCa3.1 at the basolateral membrane. For this project, 
two cell lines were used, which allowed for multiple techniques to be used. The main cell line used 
for this project was FRT-KCa3.1-BLAP cells. These cells are modified from FRT (Fischer Rat Thyroid) 
cells derived Fischer Rat thyroid glands (Zurzolo et al., 1991; Tasevski et al., 1998), through the 
stable integration of a plasmid containing KCa3.1-BLAP (Bertuccio et al., 2014) (discussed later), and 
were used for immunoblot experiments and Ussing chamber experiments. These cells are able to 
form a polarised monolayer, allowing for the membrane population of KCa3.1 to be measured at the 
basolateral membrane, making them ideal for both immunoblot and Ussing chamber experiments, 
while unmodified FRT cells served as control cells. FRT-KCa3.1-BLAP cells were cultured in Nutrient 
Mixture F-12 (Catalogue# 21700075, Ham’s F-12; Invitrogen, Carlsbad, CA, USA), modified with 10% 
(v/v) foetal bovine serum (FBS), and 1% (v/v) penicillin/streptomycin (penstrep). Cellular media was 
further modified with the glycopeptide antibiotic Zeocin (850 μg/mL), which prevented the removal 
of the plasmid from the cells.  
 The other cell line used for this project were COS-7 cells. These cells are fibroblast like cells 
derived from African green monkey kidneys (Gluzman, 1981). These cells were selected due to their 
high transfection efficiency (Felgner et al., 1987; Aleksic et al., 1996). Unlike the FRT-KCa3.1-BLAP 
cells used for immunoblot and Ussing chamber experiments, COS-7 cells do not possess the ability to 
form a polarised monolayer, instead, they were used to transiently express KCa3.1-HA-pcDNA3.1. 
These cells were cultured in a growth media consisting of DMEM (Catalogue# 12100-046, Dulbecco’s 
Modified Eagle Medium; Gibco, ThermoFisher Scientific, Waltham, Massachusetts, USA) modified 
with 10% (v/v) FBS.  
Figure 3.1 – Schematic diagram showing Transwell TM/Snapwell TM permeable support showing the apical and 
basolateral compartments, the location of the permeable support, and the support ring, which prevents the 
permeable support from touching the base of the container. Pilmore, Unpublished.  
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All cells were grown cultured in 25 cm2 cell culture flasks (Catalogue# 136196, NuncTM Cell 
Culture Treated EasYFlasksTM) at 37○C in 5% CO2. For immunoblot experiments, FRT-KCa3.1-BLAP cells 
were seeded in TranswellTM permeable supports in order to achieve polarity (Figure 3.1). For Ussing 
chamber experiments, FRT-KCa3.1-BLAP cells were seeded on SnapwellTM filters in order to achieve 
polarity on a filter to fit the Ussing chamber apparatus (Figure 3.1). In addition to using lysates from 
both FRT-KCa3.1-BLAP and COS-7 cells, HEK293 (Human Embryonic Kidney) cell lysate was used as a 
positive control for both the SNX1 and SNX27 antibodies. HEK293 lysate was obtained from the 
McDonald Lab. 
Finally, the Escherichia coli (E.coli) bacteria (strain DH5α) transformed with a plasmid coding 
for KCa3.1 containing an HA tag (KCa3.1-HA) were cultured to amplify this plasmid that was then 
extracted, purified, and transfected into mammalian COS7 cells. This allowed for non-membrane 
bound KCa3.1 to be observed by immunoblot, as the KCa3.1-BLAP model exclusively presented 
membrane bound KCa3.1. Bacteria harbouring the KCa3.1-HA plasmid were grown in a selection 
media of LB media (10g Bacto-tryptone, 5g yeast extract, 10g NaCl in 1L mqH2O) containing 
ampicillin (0.1% v/v) overnight at 37 °C on a shaker. Following this, the plasmid DNA was extracted 
through the use of a NucleobondTM Xtra midiprep kit, which contains all of the buffers used in this 
section unless otherwise stated (Catalogue# 740410.50, Machery-Nagel, Bethlehem, Pennsylvania, 
USA) as outlined briefly in section 3.5.1.  
3.2 Molecular Biology 
As stated previously, the FRT-KCa3.1-BLAP cells used for this project originate from 
unmodified FRT cells that had been transfected with a plasmid containing KCa3.1-BLAP (biotin ligase 
acceptor peptide) – BirA (biotin ligase enzyme) – KDEL construct using Lipofectamine 2000TM 
(Catalogue# 11668019, Invitrogen, Carlsbad, CA, USA). This stable transfection introduced the BirA 
enzyme, which contains an endoplasmic reticulum retention motif (KDEL) behind the human 
cytomegalovirus (CMV) promoter of the bicistronic, or dual gene, plasmid pBudCE4.1. The 
pBudCE4.1 plasmid was created by amplifying KCa3.1-BLAP DNA from pcDNA3.1, which was then 
subcloned into the pBudCE4 plasmids, forming the pBudCE4.1 plasmid (Figure 3.2) (Balut et al., 
2010). This plasmid created a cellular model where the KCa3.1 channel undergoes a process known 
as “internal biotinylation”.  
Internal biotinylation was first reported in 2005 by Alice Ting, when she used streptavidin to 
label cell surface epidermal growth factors in HeLa cells (Chen et al., 2005). The Devor Lab then 
further developed this technique in order to allow for membrane specific detection of KCa3.1 in 
polarised epithelial cells (Figure 3.3) (Balut et al., 2010; Gao et al., 2010). In short, KCa3.1 in the cells 
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contains a biotin ligase acceptor peptide (BLAP) which is located on the extracellular loop between 
the S3 and S4 domains. This BLAP sequence undergoes biotinylation in the endoplasmic reticulum as 
a result of BirA, which localises to the endoplasmic reticulum. After leaving the ER, the biotin-tagged 
KCa3.1 is trafficked to the basolateral membrane. Neither the trafficking nor function of KCa3.1 is 
changed by the addition of either the BLAP sequence or the extracellular biotin (Gao et al., 2010).  
3.3 Transfections 
3.3.1 Protein expression knockdowns 
For this project, FRT-KCa3.1-BLAP cells were transfected with silencing RNA (siRNA), in order 
to decrease synthesis of specific proteins. The relative KCa3.1 membrane population was first 
quantified by immunoblot, following which, differences in membrane populations of KCa3.1 in the 
knockdown cells compared to the control cells were determined. The FRT-KCa3.1-BLAP cells were 
used for both IB and Ussing chamber experiments, and these experiments were paired, so that the 
knockdown of the specific protein caused by transfection with siRNA measured for IB would be the 
same as the knockdown found in the Ussing chamber experiments. Similarly, the KCa3.1 membrane 
population was measured through dual experiments of IB and Ussing chamber experiments. 
The knockdowns performed in this project were performed through forward transfection of 
FRT-KCa3.1-BLAP cells. In order to perform a forward transfection, the cells were seeded the day 
before the transfection, so that cells were in the growth phase during the transfection, increasing 
the amount of siRNA taken up. The siRNA used for this project (discussed later), was transfected into 
the cells through the use of two reagents; Lipofectamine 3000 and p3000 (used in a 3:2 ratio) 
(Catalogue# L3000015, Life Technologies, Thermo Fischer Scientific Inc, Waltham, MA, USA). The 
oligonucleotide sequences of the siRNA used for this project are shown in table 3.6. Transfections 
were performed in the presence of F12 Serum Free Media (Catalogue# 21700075, Ham’s F-12; 
Invitrogen, Carlsbad, CA, USA). In order to transfect 40 pM of siRNA, either control siRNA or protein 
specific siRNA, 50 µL of Serum Free Media was put into two separate 1.5 ml tubes. To the first tube, 
3 µL of Lipofectamine 3000 was added, and to the second tube, 2 µL of P3000 was added, followed 
by 40 pM of siRNA. These tubes were then individually vortexed, before being combined and 
vortexed again, to ensure that everything mixed. The tube was then incubated at room temperature 
for 15 min, during which time, the media on the cells being transfected was changed from the 
growth media discussed earlier to the serum free transfection media. After the incubation period, 
the media from the tube was added to the apical media of the cells being transfected, and the 
transfection was left to incubate for 6 hr in the incubator, following which, the media was changed 
back to growth media and the cells were left to grow for 48 hr to ensure confluence.  
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3.3.2 Plasmid transfections 
In order to express KCa3.1-HA, COS7 cells were transfected with plasmid encoding KCa3.1-HA. 
Like with the transfections performed earlier, these transfections were forward transfections. The 
main difference between the plasmid transfection here and the siRNA transfections discussed 
above, is that the plasmid transfections involved transfecting 1 µg of plasmid protein, while siRNA 
transfections involved transfecting 40 pM siRNA. The other difference is that plasmid transfections 
were performed on 6 cm plates seeded with 1x106 cells. 
Like the siRNA transfections, 50 µL of transfection media was added to two 1.5 ml tubes, and 
either 3 µL of Lipofectamine 3000 or 2 µL of P3000 + 1 µg was added to one tube. Each tube was 
then vortexed, the tubes mixed together, and the final tube vortexed again before being incubated 
at room temperature for 15 min. The growth media on the cells was then removed, replaced with 
transfection media, and the transfection media from the tube was added to the cells and incubated 




Figure 3.3 – Cellular process outlining the addition of biotin (B) to the biotin ligase acceptor peptide (BLAP)  
sequence of KCa3.1 in polarised epithelial cells. When KCa3.1 is synthesised in the ER, the biotin ligase 
enzyme, BirA attaches a biotin molecule to the BLAP sequence, which exits on the loop between the 3rd and 4th 
transmembrane domains. Following this, KCa3.1 traffics normally to the basolateral membrane, where the 
loop between the 3th and 4th transmembrane domains is an extracellular loop. When biotin is attached to this 
loop, it provides an extracellular biotin to label, allowing for membrane selective labelling of KCa3.1 with 
streptavidin. Then antibodies for streptavidin can be used to detect this KCa3.1-BLAP-streptavidin construct. 
Pilmore, Unpublished.  
Figure 3.2 – The pBudCE4.1 plasmid. The KCa3.1-BLAP gene is located between Xho1 (A) and Kpn1 (B), and the 
BirA-KDEL gene is located between Hind3 (C) and Sal1 (D). Pilmore, Unpublished.  
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3.4 Western Blotting 
Western blots or immunoblots (IB) were used to measure the levels of KCa3.1 protein at both 
the apical and the basolateral membrane of polarised epithelial cells. To produce a successful IB, 
there are several important steps which must take place, which are outlined below. 
3.4.1 Labelling of KCa3.1 and cell lysis 
Once the FRT-KCa3.1-BLAP cells are grown to confluency on polarised filters, the membrane 
bound KCa3.1 is able to be labelled by incubating either the apical or the basolateral membrane in 
0.1% streptavidin in PBS/BSA (v/v) for 25 min at 4○C (10% bovine serum albumin in phosphate 
buffered saline). The cells were then washed in ice cold PBS/BSA three times for five min each wash. 
A final wash in ice cold PBS for five min was finally carried out to remove any remaining PBS/BSA 
prior to cell lysis. It was important that both the labelling of KCa3.1 with streptavidin and washing 
cells with PBS/BSA are carried out at 4○C in order to prevent internalisation of KCa3.1 so that only 
membrane bound KCa3.1 channels are visualised in immunoblot experiments through the use of an 
anti-streptavidin antibody. Once the cells have been labelled, the cells are ready to undergo lysis. 
This was completed by incubating cells in 130 μL lysis buffer on the apical membrane for 15 min (40 
μL EDTA free protease inhibitor and 960 μL lysis solution; HEPES 50 mM, EDTA 1 mM, NaCl 150 mM, 
and Triton 5 mL; made up to 500 mL with ddH2O). The lysed cells were then scraped off the 
membrane and transferred to a microcentrifuge tube, which was spun at 14000g for 10 min at 4○C in 
order to separate the proteins from the lipids. The supernatant, containing the proteins, was 
transferred to a fresh microcentrifuge tube, while the pellet containing lipids was discarded.  
3.4.2 Protein sample analysis 
In order to determine the volume of cellular lysate to load for IB the protein concentration of 
the lysates were analysed in a Bicinchoninic acid (BCA) assay (Smith et al., 1985). The BCA assay 
determined the protein concentration through the use of three reagents; A, B, and S (Catalogue# 
5000111, BioRad, Hercules, Ca, USA), and protein standards of known concentrations. For the BCA 
assay, 6 μL of protein standard (Bovine Serum Albumin) or cellular lysate was loaded in triplicate into 
a 96 well plate. This was followed by the addition of either 30 μL of reagent A (for protein 
standards), or 30 μL reagent AS (1 mL reagent A and 20 μL reagent S, for cellular lysates), and finally 
the addition of 240 μL reagent B. The absorbance of the BCA assay was the measured through the 
use of a Synergy 2 Multi-Mode Microplate Reader set to measure absorbance at 630 nm, and the 
absorbance results quantified using Gen5 software (Biotek, Winooski, VT, USA).  
In order to then calculate the concentration of the cellular lysate, first, the absorbance of each 
of the protein standards were determined, creating a protein concentration curve. Following this, 
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the absorbance of the lysates were measured and the protein concentration is calculated by using 
the protein concentration curve set by the protein standards.  
3.4.3 Sodium Dodecyl Sulphate Poly-Acrylamide Gel Electrophoresis 
Sodium dodecyl sulphate poly-acrylamide gel electrophoresis (SDS-PAGE) is a process that acts 
to separate proteins based on molecular weight. This occurs because sodium dodecyl sulphate (SDS) 
has a negatively charged head with a lipophilic tail, which allowing for SDS to bind non-covalently 
with proteins, conferring a negative change onto them (Weber & Osborn, 1969; Rath et al., 2009). 
SDS binds proteins in a ratio of 1:4, and acts to linearise proteins, resulting in the secondary, tertiary, 
and quaternary bonds found in proteins being converted from secondary, tertiary, and quaternary 
protein bonds into primary bonds (Reynolds & Tanford, 1970; Rath et al., 2009). 
The other aspect of SDS-PAGE is the poly-acrylamide gel electrophoresis (PAGE), and is a 
process whereby proteins that have been loaded into a polyacrylamide gel are separated based on 
molecular weight. This technique is based on the principle that negatively charged particles will 
move towards a positively charged region of an electric field (Ganguli, 1956). In PAGE, the negatively 
charged proteins migrate from the cathode, which itself is negatively charged, to the positively 
charged anode. This allows for the proteins to be separated by molecular weight, as higher 
molecular weight proteins will encounter more resistance than lower molecular weight proteins, 
thus, the high molecular weight proteins will lag behind their smaller molecular weight counterparts 
(Shapiro et al., 1967; Weber & Osborn, 1969). A protein ladder, which contains a negatively charged, 
prestained proteins of known sizes is also run on the PAGE, allowing for protein size to be calculated 
depending on their location relative to the ladder.  
SDS-PAGE acrylamide gels were created using the volumes listed below in Table 3.2. The 
volume of each reagent to make resolving gels changes depending on the desired acrylamide 
percentage gel, which are shown in Table 3.1. In order to determine what percentage gel to make, it 
is important to know the sizes of the proteins which are desired to be visualised. Once the desired 
protein range was calculated, the desired resolving gel was made, for example, the 79 kDa protein 
KCa3.1 was detected using an 8% gel, as was the 59 kDa protein SNX1, the 60 kDa protein SNX4, and 
the 61 kDa protein SNX27. This involved preparing the gel solution, and pouring 10 mL of the 
solution into a watertight gel cassette, followed by 1 mL of water-saturated butanol in order to 
remove air bubbles and prevent evaporation whilst the resolving gel was setting. After the resolving 
gel was set, butanol was poured off, and a further 2 mL of stacking gel was added to the gel. A comb 
was then added before the stacking gel set, so that wells were created in the stacking gel for protein 
loading (Figure 3.4).  
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Table 3.1 – Protein size to polyacrylamide gel table. All proteins desired to be visualised by IB should be 
within the protein size range of the gel being made (Abcam, 2015).  
 
Table 3.2 – Ingredients for the preparation of gels to run SDS-PAGE electrophoresis 
Ingredients 8% Resolving 







H2O 4.6 mL 3.8 mL 3.2 mL 3 mL 
1.5M Tris pH 8.8 2.6 mL 2.6 mL 2.6 mL  
0.5M Tris pH 6.8    1.25 mL 
10% SDS 100 μL 100 μL 100 μL 50 μL 
30% Acrylamide/Bis-
acrylamide 
2.6 mL 3.4 mL 4 mL 665 μL 
10% APS 50 μL 50 μL 50 μL 25 μL 
TEMED 10 μL 10 μL 10 μL 5 μL 
 
Once the gels had set, they were moved to vertical running frames (Catalogue# EC120, 
ThermoEC, Holbrook, New York) in a gel tank, which was filled with running buffer. 10 μL of 
prestained protein ladder (Catalogue# 10748010, Benchmark, Invitrogen, Carlsbad, CA, USA) was 
loaded into the 1st well, followed by protein samples mixed with sample buffer (500µL 5x βME free 
sample buffer (3 mL 20% SDS, 3.75 mL 1M Tris buffer pH 6.8, 9 mg bromophenol blue, 4.5 mL 
glycerol, adjusted to 15 mL with H2O) and 10µL βME) in subsequent wells. The volume of protein 
Protein size range (recommended) (kDa) Polyacrylamide gel percentage 
40 – 200  8% 
30 – 200  10% 
20 – 150 12% 
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sample loaded were determined via BCA protein assays so that 30 μg of protein was added to each 
lane. The gels were then run for 90 min at 140 V to completely separate the proteins.  
3.4.4 Transfer of Proteins from Gel to Membrane 
Once the SDS-PAGE gels have separated out the proteins sufficiently, it was necessary to 
transfer the proteins from the gel to a more durable structure, such as a polyvinylidene fluoride 
(PVDF) membrane (Catalogue# 88518, Thermo Fischer Scientific Inc, Waltham, MA, USA). This PVDF 
membrane is necessary in order to incubate the proteins in primary and secondary antibodies to 
allow for visualisation. In order to transfer the proteins from the gel to the PVDF membrane so that 
the proteins retain the separation achieved during SDS-PAGE, the gel with proteins attached and a 
blank, activated piece of PVDF membrane (PVDF membrane activated via incubation in methanol for 
20 seconds) are sandwiched together between pieces of filter paper which have been soaked in 
transfer buffer (25 mM Tris, 120 mM Glycine; made to 1L with ddH2O.  
It is important to ensure that the filter paper on the cathode side (Figure 3.5) is rolled out 
thoroughly in order to remove any air bubbles, as these could result in sections of the gel not being 
Figure 3.5 – Transfer of proteins from the polyacrylamide 
gel to the PVDF membrane. As it is in SDS-PAGE, protein 
transfer moves proteins from the cathode to the anode. 
However, unlike in SDS-PAGE, where proteins are able to 
run off the gel, the Polyvinylidene fluoride (PVDF) 
membrane is non-porous, so proteins cannot be 
transferred through the membrane and onto the filter 
paper. Pilmore., Unpublished. 
Figure 3.4 – SDS-PAGE acrylamide gel. In SDS-
PAGE, proteins stack together when moving 
through the stacking gel, allowing for accurate 
size based separation when flowing through the 
resolving gel. Pilmore., Unpublished. 
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transferred onto the PVDF membrane. Transfers were run using a Semi-Dry transfer system (TE 77 
PWR Semi-Dry transfer unit, Amersham ECL Semi-Dry Blotters, GE Healthcare Life Sciences), which   
was run for 2 hr at 45 mA per gel.  
3.4.5 Blocking the PVDF membrane 
Once all of the proteins from the SDS-PAGE acrylamide gel have been transferred to the 
activated PVDF membrane, protein detection is able occur. However the accuracy of protein 
detection can be significantly improved by first binding non-specific proteins to any empty areas of 
the PVDF membrane. This is necessary as proteins bind to the PVDF membrane with an extremely 
high affinity, meaning that proteins can “accidentally” bind to the PVDF membrane (Matsudaira, 
1987). In order to bind non-specific proteins to the empty areas of the PVDF membrane, the 
membrane is immediately immersed in a blocking solution of 5% low-fat (0.1% fat) diary milk 
powder in Tris-buffered saline – Tween (TBS-T; 10mM Tris-HCL, 100mM NaCl, made to 1L with 
ddH2O, 0.1% Tween-20 v/v, pH 7.4) for one hr at room temperature. The proteins in this solution do 
not react with the primary antibody used for protein detection, meaning that only the proteins 
detected are from cell lysates. 
3.4.6 Antibodies 
After the PVDF membrane has been blocked in 5% non-fat dairy milk powder in TBS-T for an 
hr, the membrane is ready to be incubated in the primary antibody used to detect a specific protein. 
The primary antibody is diluted in TBS-T at a concentration between 1/1000 and 1/10,000, 
depending on the antibody (discussed later). In order to obtain optimal visualisation of protein, the 
PVDF membrane is incubated in primary antibody overnight at 4○C on a shaker. After this incubation, 
the primary antibody removed and the PVDF membrane was washed in TBS-T for three 10 min 
washes. The appropriate secondary antibody is then selected, in order to react with the primary 
antibody. The secondary antibody is required as it is conjugated with horseradish peroxidase (HRP), 
which fluoresces when activated with a LumilightTM solution. This secondary antibody is also diluted 
in TBS-T and incubated for one hr at room temperature on a shaker. Finally, the secondary antibody 





Table 3.3 – Table showing antibodies used. Antibodies used for this project showing what the antibody 
reacts to, the animal in which the antibody was purified in, the amount the antibody was diluted in TBS-T by to 
reach working concentration, and the catalogue number. Additional information regarding these antibodies is 
in section 2.9.1. 




 anti-Streptavidin Rabbit 1:1000 Genscript A00621-10 
anti-GAPDH Rabbit 1:2000 Sigma Aldrich g8795 
anti-SNX1 Goat 1:1000 Abcam ab134126 
anti-SNX4 Rabbit 1:1000 Abcam ab170562 
anti-SNX27 Rabbit 1:1000 Abcam ab178388 




 anti-rabbit  Donkey 1:5000 GE Healthcare NA934-1ML 
anti-goat Donkey 1:10000 Santa Cruz sc-2020 
 
3.4.7 Visualisation of proteins 
After the proteins of interest on the PVDF membrane have been treated with both primary 
and secondary antibody, the proteins can be visualised. This is achieved through the use of a 
LumilightTM solution (Roche, Basel, Switzerland), which reacts with the HRP conjugated secondary 
antibody. This reaction causes light to be released due to the oxidation of luminol in the Lumilight 
solution. This light occurs only where antibodies are bound, and the light is captured by Carestream 
Kodak Biomax Film (Catalogue# Z350370, Sigma Aldrich, St Louis, Missouri, USA) (Thorpe et al., 
1985). As the Kodak Biomax Film is extremely sensitive to light, exposure of the film is minimised to 
only capturing light released from the PVDF membrane by performing the exposure in a darkroom. 
The film is then subsequently developed by immersing it in a developer solution (1 part developer: 4 
parts water) (Catalogue# 183 8374, Rapid Access Developer, Carestream Dental, Atlanta, Georgia, 
USA) followed by rinsing any remaining developer solution off in water, and immersion in a fixer 
solution (1 part developer: 4 parts water) (Catalogue# 183 8374, Rapid Access Fixer, Carestream 
Dental, Atlanta, Georgia, USA). 
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3.5 KCa3.1-HA DNA preparation 
3.5.1 Bacterial lysis and KCa3.1-HA isolation 
For this project, a KCa3.1 channel containing an HA tag was planned to be used for 
immunoprecipitation experiments. The KCa3.1-HA plasmid for this project was generously donated 
by the Devor Lab from the University of Pittsburgh. The E.Coli containing the KCa3.1-HA plasmid was 
stored as a glycerol stock at -80 ○C. Bacterial growth is outlined in section 2.1, and, as with all cellular 
experiments, the first step of this was to lyse the bacteria in order to obtain the plasmid DNA. This 
was performed by centrifuging the bacteria at 6000g for 15 min at 4 °C to obtain a bacterial pallet, 
which was then resuspended in Resuspension Buffer RES, and lysed through the addition of 8 mL of 
Buffer LYS, which contains sodium hydroxide/SDS, and 8 mL of the Neutralising Buffer NEU and 
incubated for 5 min at room temperature. The addition of Buffer NEU allows for proteins and cellular 
debris to precipitate out of solution, while plasmid DNA remains soluble. Following this, the lysate 
was filtered through a NucleobondTM Xtra Column Filter which had been washed with 15 mL of 
Equilibration Buffer EQU and allowed to empty by gravity flow. The filter was then washed with 5 mL 
of Buffer EQU, and the column was subsequently washed without the filter with 8 mL of buffer 
WASH. Any plasmid DNA bound to the column was then eluted from the column through the 
addition of 5 mL of Elution ELU Buffer ELU. Isopropyl alcohol was then added to the eluted solution, 
caused the previously soluble plasmid DNA in solution to precipitate, and the solution was separated 
by centrifuging the solution at 4 °C for 30 min. The supernant was discarded, and the pellet washed 
by being resuspended in 2 mL of 70% ethanol, before being centrifuged at 15000g for 5 min at room 
temperature. Finally the ethanol was carefully removed, and the pellet was allowed to dry at room 
temperature. The dry DNA pellet was resuspended and stored in TE buffer (10 mM Tris, 1 mM EDTA, 
pH 8.0), and the concentration of the DNA was determined by Nanodrop.  
3.5.2 Restriction digest 
Once the plasmid DNA was extracted and stored in TE buffer, a Restriction digest was 
performed in order to ensure that the plasmid purified indeed contained KCa3.1-HA. This was done 
through the use of two restriction enzymes, EcoR1 (Catalogue# 10703737001, Roche Applied 
Science, Penzburg, Germany) and Xho1 (Catalogue# 10703770001, Roche Applied Science), as 
described by Syme and colleagues (Syme et al., 2003). Three digests were performed; a negative 
control digest (uncut), a single cut digest, and a double digest, as shown in Table 3.4. Each of the 
digests contained 0.5 µg of plasmid DNA, as determined previously by nanodrop measurement. 
Additionally, 3 µL of Buffer H (Sigma Aldrich, St Louis, Missouri, USA) was used, as it is the optimised 
buffer for these restriction enzymes. The 1.5 mL tubes containing each of these mixes were 
incubated at 37 °C for 1 hr to ensure digestion.  
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Table 3.4 – Table showing the ingredients used in restriction digests to isolate KCa3.1-HA 
Ingredients Uncut digest Single cut digest Double Digest 
KCa3.1-HA plasmid 0.5 µg 0.5 µg 0.5 µg 
Buffer H 3 µL 3 µL 3 µL 
EcoR1 enzyme  1 µL 1 µL 
Xho1 enzyme   1 µL 
Water 26 µL 25 µL 24 µL 
 
The products of the restriction digest were then treated with DNA loading dye (Catalogue# 
R0611, Thermo Fischer Scientific Inc, Waltham, MA, USA), in order to stop the digestion reaction, 
and to convey a negative charge onto the plasmid proteins. This loading dye contains both 
bromophenol blue and xylene cyanol FF in order to track DNA movement, along with EDTA in order 
to bind divalent metal ions and inhibit metal-dependent nucleases. The proteins from the restriction 
digest were then run on a 1% agarose gel with TAE (Tris, Acetic acid, EDTA buffer; 40 mM Tris, 20 
mM acetic acid, 1 mM EDTA, made to 1L in ddH2O) for 30 min at 100V, before being visualised 
through use of ultraviolet light. 
3.6 Ussing chamber 
In conjunction with IB experiments, which measured the membrane population of KCa3.1, 
functional studies measuring transepithelial ion transport through the KCa3.1 channel were also 
performed. These functional studies are vital to understand the effects of knockdown of 
components of the Retromer pathway on KCa3.1, as the ability of cells to transport K+ ions is reliant 
on both adequate membrane populations of KCa3.1, and that KCa3.1 has an adequate open 
probability. These functional experiments were completed through the use of an Ussing chamber 
apparatus. The Ussing chamber apparatus consists of two identical chambers, giving the ability to 
control the extracellular solution on the apical and basolateral membranes independently (Ussing & 
Zerahn, 1951), as well as a space to put an insert containing cells to measure. 
Ussing chambers measure changes in the short circuit current (ISC) across tissue, or, in this 
case, a cellular monolayer, by measuring the current of the apical and basolateral extracellular fluids. 
Two current sensing electrodes, one for the apical chamber, and one for the basolateral chamber 
(Figure 3.6) calculate the transepithelial current and two additional voltage sensing electrodes 
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3.6.1 Ussing chamber cell culture 
For the Ussing chamber experiments, FRT-KCa3.1-BLAP cells were grown to form a polarised 
monolayer by seeding cells onto SnapwellTM filters 72 hr prior to the experiment (Figure 3.1). This 
ensured a fully confluent monolayer without achieving cellular overgrowth. This method of cell 
growth is similar to the method used to grow a confluent cellular monolayer for IB experiments. 
3.6.2 Modified Ringer’s Solution 
 For Ussing chamber experiments, the epithelia is surrounded by a solution known as Ringer’s 
solution. This solution acts to mimic the extracellular fluid, containing ions to be exchanged in the 
cells, as well as glucose to provide cellular energy. This creates an environment where cells are able 
to function normally, allowing for ion channel activity to be measured. In the case of KCa3.1, 
however, standard Ringer’s Solution is replaced in favour of a modified Ringer’s Solution.  
Table 3.5 – Modified Ringer’s Solution. Ingredients for the modified Ringer’s solution used for Ussing 
chamber experiments. Both the concentration of each ingredient and the weight of each ingredient for 1L of 
solution are listed, and the Ringer’s solutions were adjusted to a pH of 7.4.  
 
This modified solution is similar to standard Ringer’s Solution, however, is modified for use in 
either the apical or basolateral Ussing chambers, and contains increased CaCl2 (4 mM compared to 
1.2 mM found in standard Ringer’s Solution) in order to compensate for the Ca2+ buffering effect of 
Ingredients Apical Ringers solution  Basolateral Ringer’s 
solution 
Potassium Gluconate 145 mM  5 mM  
Sodium Gluconate  145 mM  
HEPES 10 mM  10 mM  
Magnesium Chloride (hexahydrate) 1 mM 1 mM  
Calcium Chloride 4 mM 4 mM  
Glucose 10 mM 10 mM  
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the gluconate anions present (Durham, 1983; Ryabov et al., 1999) (Table 3.5). These solutions 
created an artificial K+ gradient by exaggerating K+ concentration differences, as well as removing 
apical Na+ transport; which leads to an overall amplified K+ current through KCa3.1, allowing for 
more accurate measurement of changes in KCa3.1 activity.  
3.6.3 Ussing chamber set up 
Prior to use of the Ussing chamber apparatus, some crucial elements must be set up. Firstly, 
the modified Ringer’s solutions outlined in section 3.6.2 must be warmed in a water bath to 37○C in 
order to keep the “extracellular” environment as close to physiological conditions as possible. 
Secondly, the current- and voltage-sensing electrodes must be created. This is done by filling the tips 
of empty plastic electrodes with agar gel (3% agar in 3M KCl (v/v)). Once the agar was set, the 
remainder of the electrode was filled with 3M KCl solution, and the end capped with either a 
voltage- or current-sensing electrode. Finally, the completed electrode was checked to ensure that 
there were no air bubbles, as these would reduce the effectiveness of the electrodes.  
Once the Ringer’s Solution was warmed and the electrodes were made, wires were plugged 
into the electrodes, and an empty Snapwell filter was placed into the middle of the Ussing chamber 
(Figure 3.6). The chambers were then filled with Apical Ringer’s Solution, and the electrodes were 
zeroed in preparation to accurately measure the current and resistance of the cellular monolayer 
Figure 3.6 – Ussing chamber setup. The apical and basolateral chambers are set up to contain distinct 
solutions, and are connected through the insertion of a Snapwell insert. Current, voltage, and resistance are 
measured through the use of two pairs of current and voltage sensing electrodes, which are inserted into each 
chamber, as shown, with V representing the voltage sensing electrode, and I representing the current sensing 
electrode. Finally, solutions and oxygen are fed into each chamber through the holes at the top of the 




being tested. A Snapwell filter containing a confluent cellular monolayer was inserted into the 
system, and apical and Basolateral Ringer’s Solutions were added to the apical and basolateral 
chambers. The recording was then begun, allowing for measurement of the K+ current.  
3.6.4 Measuring K+ current changes 
When the cells have been placed into the Ussing chamber, the electrodes begin to measure 
both the current and resistance in the Ussing chamber across the monolayer. When the current 
trace has stabilised, KCa3.1 ligands can be used to either open or close the channel. In order to 
stimulate KCa3.1, the ligand 1-EBIO was used, which caused an increase in the current, referred to as 
the 1-EBIO sensitive current (Devor et al., 1996). Conversely, in order to inhibit the channel, 
clotrimazole was used (Devor et al., 1997), leading to a decrease in the current, denoted as the 
clotrimazole sensitive current. When measuring the K+ current, first the current must be stable, or 
not fluctuating, so that an accurate change in current can be measured, and the transepithelial 
resistance must be over 500 Ω·cm2. When both of these criteria were met, 100 µM of 1-EBIO was 
added to both the apical and basolateral chambers. The current was then allowed to stabilize again, 
and the change in current was noted. Next, 10 µM of clotrimazole was added to both the apical and 
basolateral chambers, and the current was allowed to stabilize again. Finally, the clotrimazole 
sensitive change in current was noted. For this experiment, the change in current was measured by 
the vertical change in current (Δy) before and after the addition of either 1-EBIO or clotrimazole.  
3.7 Chemicals 
3.7.1 Zeocin 
Zeocin (phleomycin D) (Catalogue# R25001, Life Technologies, Thermo Fischer Scientific Inc, 
Waltham, MA, USA), is a glycopeptide antibiotic cultivated in Streptomyces verticillus. For this 
project, Zeocin is used as a component of selection media in order to keep the KCa3.1-BLAP plasmid 
expressed in the FRT cells used, maintaining the FRT-KCa3.1-BLAP cell line (section 3.1). FRT-KCa3.1-
BLAP cells contain a Zeocin resistance gene, which prevents Zeocin evoking cell death by fracturing 
double strands of DNA (Ehrenfeld et al., 1987; Chankova et al., 2007). In the inactive form, Zeocin is 
bound to a Cu2+ ion. Upon entering the cell, on the other hand, the Cu2+ ion is cleaved from Zeocin, 
allowing it to bind to DNA (Oh et al., 2002).  
3.7.2 Streptavidin 
Streptavidin (Catalogue# 434302, Life Technologies, Thermo Fischer Scientific Inc, Waltham, 
MA, USA) is a non-glycosylated homotetrameric protein which binds with a high affinity to biotin. 
This high affinity bond formed to biotin was used in order to tag KCa3.1-BLAP channels present in 
the membrane, allowing for the membrane population of KCa3.1 to be quantified via IB experiments 
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(section 3.4.1). This was possible due to the FRT-KCa3.1-BLAP cells expressing KCa3.1 with an 
extracellular biotin. Streptavidin acts by forming hydrogen bonds with biotin, following which, 
tryptophan residues interact, stabilizing the hydrogen bonds, and increasing the interaction strength 
(Kurzban et al., 1990).  
3.7.3 1-EBIO 
1-ethyl-benzimidazolone (1-EBIO) (Catalogue# SML0034-50MG, Sigma Aldrich, St Louis, 
Missouri, USA), is a Ca2+ activated K+ channel opener, found to open the KCa3.1 channel by Devor 
and colleagues (section 3.6.4) (Devor et al., 1996). Alongside Ca2+ activated K+ channels, KCa3.1 has 
also been shown to activate the cystic fibrosis transmembrane conductance regulator channel 
(CFTR) (Devor et al., 1996).  
3.7.4 Clotrimazole 
Clotrimazole (Catalogue# C6019-5G, Sigma Aldrich, St Louis, Missouri, USA), is an antifungal 
drug which was first found to inhibit the K+ current seen in cells expressing the KCa3.1 channel by 
Devor and colleagues (Devor et al., 1997), and was shown to block the KCa3.1 channel with high 
potency by Wulff (section 3.6.4) (Wulff et al., 2000). As both 1-EBIO and clotrimazole are DMSO 
soluble, it was important to not exceed a concentration of 0.5% DMSO when reconstituting either 1-
EBIO or clotrimazole in DMSO (Adefolaju et al., 2015).  
3.7.5 Lipofectamine 3000 
Lipofectamine 3000 (Catalogue# L3000015, Life Technologies, Thermo Fischer Scientific, 
Waltham, MA, USA) is a common transfection reagent. Purchase of Lipofectamine 3000 included the 
reagent P3000, and these reagents were used together in a 3:2 ratio (Lipofectamine 3000:P3000) in 
order to increase the transfection efficiency during forward transfections (section 3.3). 
Lipofectamine 3000 forms a complex with nucleic acid molecules, allowing then to overcome the 
large electrostatic repulsion of the cellular membrane and enter the cell.   
3.8 Plasmids and siRNA  
3.8.1 siRNA 
For this project, cells were transfected with either 40 pM of control siRNA, or with 40 pM of 
protein specific siRNA. All the siRNA used in this project was reconstituted in RNAse free water, 
aliquoted and stored at -20 ○C. Additionally, the three protein specific siRNAs used for this project 
(SNX1 siRNA (Catalogue# NM_053411), SNX4 siRNA (Catalogue# NM_001127550), and SNX27 siRNA 
(Catalogue# NM_001110151)) were all purchased from Sigma Aldrich (Sigma Aldrich, St Louis, 
Missouri, USA). Oligonucleotide sequences for the siRNA used are shown in table 3.6 below. 
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Control siRNA was used as a negative control for this project, and was transfected into cells at 
the same concentration as the SNX siRNAs. The control siRNA used for this project was custom made 
by Sigma Aldrich (Sigma Aldrich, St Luis, Missouri, USA). 
Table 3.6 – Oligonucleotide sequences for the siRNA used for knockdown transfections 
siRNA Sequence 
SNX1 siRNA GAAUCAUCCUACCAUGUUA 
SNX4 siRNA CUGUCAUGCAGAUCAGCAU 
SNX27 siRNA GUACUUCUUUCAUCAGGCU 
Control siRNA UGGAGUGAAUACCACGACGAU 
 
3.8.2 KCa3.1-HA 
The KCa3.1-HA plasmid for this project was generously donated by the Devor Lab from the 
University of Pittsburgh. This plasmid contains the gene encoding KCa3.1-HA inserted into the 
pcDNA3.1 plasmid through the use of EcoR1 and Xho1 restriction enzymes, and the pcDNA3.1 
plasmid was transformed into the E-Coli strain DH5α. The E-Coli were stored in a glycerol stock at -
80 ○C. In order to extract the KCa3.1-HA plasmid, the E-Coli was grown in LB media overnight, and 
the pcDNA3.1 plasmid extracted through the use of a DNA purification kit. The extracted plasmid 
was stored in RNAse free water at -20 ○C, and transfected into cells via forward transfection with 
Lipofectamine 3000 as described in section 3.6.2.  
3.9 Antibodies 
3.9.1 Primary antibodies 
3.9.1.1 Anti-Streptavidin 
The anti-streptavidin antibody used in this project was developed in rabbits through the use of 
polyclonal streptavidin, and is purified from rabbit anti-serum by protein G resin (Catalogue# 
A00621-10, GenScript, Piscataway, NJ, USA). The anti-streptavidin polyclonal antibody binds to 
streptavidin, which is present on membrane bound KCa3.1-BLAP, and is used at 1:1000 dilution in 
TBS-T. 
3.9.1.2 Anti-GAPDH 
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) is a protein found in FRT cells, and is 
used as an internal protein control for IB experiments. This is because, unlike other proteins, the 
concentration of GAPDH in cells remained unaffected by any of the treatments used for this project. 
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This allowed for the concentration of other proteins to be “normalised”, showing the true 
concentration of proteins, allowing for comparisons to be made between samples. The anti-GAPDH 
antibody (Catalogue# g8795, Sigma Aldrich, St Louis, Missouri, USA) was purified in rabbits, and 
HAbinds directly to GAPDH, and is diluted at 1:2000 in TBS-T. 
3.9.1.3 Anti-SNX1 
Anti-SNX1 is an antibody which binds directly to sorting nexin 1 (SNX1), and was purified in 
goats (Catalogue# ab134126, Abcam, Cambridge, UK). The anti-SNX1 antibody binds to the SNX1 
present in cell lysate, and was used at 1:1000 concentration, diluted in TBS-T. 
3.9.1.4 Anti-SNX4 
The anti-SNX4 antibody used binds to sorting nexin 4 (SNX4). This antibody was purified in 
rabbit (Catalogue# ab170562, Abcam, Cambridge, UK). This antibody was used at 1:1000, diluted in 
TBS-T. 
3.9.1.5 Anti-SNX27 
The anti-SNX27 antibody used for this project binds to the C-terminal of sorting nexin 27 
(SNX27) was purchased from Abcam (Catalogue# ab178388, Abcam, Cambridge, UK). The anti-SNX27 
antibody was purified in rabbit, and was used at a concentration of 1:1000, and was diluted in TBS-T. 
3.9.1.6 Anti-HA 
The anti-HA antibody used in this project binds to the HA protein tag. Specific proteins were 
modified to contain an HA tag, allowing for detection with the HA antibody. The anti-HA antibody 
was purchased from (Catalogue# ab137838, Sigma Aldrich, St Louis, Missouri, USA), and was purified 
in rabbit. Anti-HA was diluted to 1:1000 for use in immunoblotting.  
3.9.2 Secondary antibodies 
3.9.2.1 Donkey anti-Rabbit IgG linked Horseradish-peroxidase whole 
antibody 
The donkey anti-rabbit IgG linked Horseradish-peroxidase (HRP) whole antibody was used in 
order to visualise proteins which used a primary antibody purified in rabbit. These antibodies were 
anti-streptavidin, anti-GAPDH, anti-SNX4, anti-SNX27, and anti-HA primary antibodies. The donkey 
anti-rabbit IgG linked HRP whole antibody was purchased from GE Healthcare (Catalogue# NA934-
1ML, GE Healthcare, Chicago, IL, USA). As with all HRP linked whole antibodies, the donkey anti-
rabbit IgG linked HRP whole antibody reacts with luminol in order to produce a low intensity light in 
the areas to which it has bound. This light is able to be detected by film, allowing for specific protein 
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expression to be quantified. The dilutions used for this antibody varied from 1:2000 to 1:10,000 
depending on the primary antibody used in order to optimise fluorescence. 
3.9.2.2 Donkey anti-Goat IgG linked Horseradish-peroxidase whole 
antibody 
Similar to the donkey anti-rabbit IgG linked HRP whole antibody, the donkey anti-goat IgG 
linked HRP whole antibody was used in order to visualise proteins bound to primary antibodies 
purified in goat. This antibody was anti-SNX1 for this project. The donkey anti-goat IgG linked HRP 
whole antibody was purchased from Santa Cruz Biotechnology (Catalogue# sc-2020, Santa Cruz 
Biotechnology, Dallas, TX, USA). This antibody was used at a 1:2000 dilution. 
3.10 Statistical analysis 
The data for this project was analysed through the use of Microsoft ExcelTM 2013, ImageJ, and 
Graphpad Prism 6. In order to analyse IB blot data, the protein of interest was quantified through 
the use of ImageJ software (imagej.nih.gov/ij), following which, the proteins were normalised to the 
GAPDH control protein through Microsoft ExcelTM. This prevented analysis errors as differences in 
protein loading were able to be easily corrected. Ussing chamber data was analysed by transferring 
the trace data into Microsoft ExcelTM and the change in current was measured upon the addition of 
both 100 µM 1-EBIO and 10 µM clotrimazole. The results from both of these were uploaded to 
Prism, in order for statistical analyses to be carried out. In order to gain accurate statistical results, 
way ANOVA analyses was carried out within each data set for data with more than two groups, while 
paired t-tests were performed for data sets with only two groups. This allowed for the significance of 
change between groups to be accurately observed. An additional test for outliers (ROUT outlier test) 
was also carried out for each data set, and any outliers were omitted from data sets to ensure 





4 Results  
Sorting nexins (SNX) are a large group of proteins, with 33 identified members in mammals 
(Cullen, 2008). SNX proteins interact strongly with the early endocytic network (Seet & Hong, 2006), 
and some portray a specialised role in vesicle formation through the presence of a BAR domain 
(Zimmerberg & McLaughlin, 2004; Frost et al., 2008). The presence of this BAR domain presents a 
role of SNX proteins in channel recycling. While it is unknown if KCa3.1 is recycled, a relationship 
between SNX proteins and KCa3.1 could indicate the potential for recycling. The aim of this project 
was to examine the role of three sorting nexins, SNX1, SNX4, and SNX27, which might be involved in 
the Retromer pathway, in the basolateral trafficking and function of KCa3.1 in a polarised 
epithelium.  
4.1 Confirmation of basolateral localisation of KCa3.1 
Before this investigation began, it was important to ensure that KCa3.1 was localised to the 
basolateral membrane of the polarised FRT-KCa3.1-BLAP epithelial cells. This experiment, known as 
a sidedness experiment, was accom08plished by seeding cells onto filters, and growing the cells until 
the cells formed a confluent monolayer, as determined through visualisation by light microscope. 
Figure 4.1 – Sidedness experiment displaying the membrane localisation of KCa3.1. A. Representative blot 
demonstrating KCa3.1 at 79 kDa, and the loading control GAPDH at 37 kDa. Lane 1 exhibits the cells without 
KCa3.1 labelling, which was used as a negative control, lane 2 displays the apical membrane population of 
streptavidin, and lane 3 presents the basolateral membrane population of KCa3.1. B. Quantification of the 
immunoblots carried out in the sidedness experiments, normalised to the negative control. The results here 
reveal a significant increase in the basolateral membrane population of KCa3.1 compared to the negative 
control (p < 0.05; n=4), and a trend towards a significant increase in the membrane population of KCa3.1 at 
the basolateral membrane compared to the population at the apical membrane (p < 0.05; n=4). The 
presence of the non-specific 82 kDa band is consistent with previous results from the Hamilton lab using the 
KCa3.1-BLAP model, and does not interfere with KCa3.1.ANOVA analyses were performed between each 
group in B to assess significance between each group. 
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Once this confluency was reached, the membrane bound biotinylated KCa3.1 was labelled with 
streptavidin. Streptavidin was added to either the apical or the basolateral membrane, allowing for 
both the apical and the basolateral membrane populations of KCa3.1 to be labelled and visualised 
independently of one another. Figure 4.1A displays a representative blot of KCa3.1 during a 
sidedness experiment, with KCa3.1 at 79 kDa, and GAPDH at 37 kDa. Lane 1 contains the negative 
control, or lysate from cells without KCa3.1 labelled with streptavidin, from cells that have 
undergone no streptavidin labelling, whilst lanes 2 and 3 contain lysate from cells with the apical or 
basolateral membrane populations of KCa3.1 labelled respectively. Figure 4.1B presents the 
quantification of these immunoblots, which demonstrates the majority of KCa3.1 was present in the 
basolateral membrane. Additionally, the difference between the apical and the basolateral 
membrane populations is significant (p < 0.05), leading to the possibility that significance would 
emerge if more experiments were carried out. The nonspecific band at 82 kDa has consistently been 
identified in immunoblots of the KCa3.1-BLAP channel (Farquhar et al., 2017). 
4.2 Antibody tests 
For this project, immunoblots were used as a primary experiment, ergo it was essential to 
ensure that each antibody used for this project was functional with lysate from FRT-KCa3.1-BLAP 
cells, and, just as importantly, to demonstrate the endogenous expression of the SNX proteins 
present in the FRT-KCa3.1-BLAP cells. These immunoblot experiments were performed by using cells 
which the antibody in question had previously been proven to detect SNX1 and SNX27 in the positive 
control (HEK 293 cellular lysate) provided by members of the McDonald lab, and FRT-KCa3.1-BLAP 
cells. Figure 4.2 demonstrates the antibody test results for both anti-SNX1 and anti-SNX27 
antibodies, which displays lysate from HEK293 cells, a positive control for both the SNX1 and SNX27 
antibodies, in lane 1, and FRT-KCa3.1-BLAP cells in lane 2. 
Figure 4.2 – Antibody test for anti-SNX1 and anti-SNX27. This figure exhibits immunoblots confirming that 
anti-SNX1 antibody detects SNX1 protein in FRT-KCa3.1-BLAP cells, and that anti-SNX27 antibody detects 
SNX27 in FRT-KCa3.1-BLAP cells. Lane 1 contains the positive control, which was lysate from HEK293 cells. Lane 
2 consists of lysate from FRT-KCa3.1-BLAP cells, which were not labelled with streptavidin (n=3).  
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4.3 siRNA tests  
Aside from the sidedness experiment and the antibody tests, the final preliminary experiment 
to carry out before the onset of this project was to determine the effectiveness of the SNX1 and 
SNX27 siRNAs on the protein population of SNX1 and SNX27 respectively. This was done by 
transfecting cells with increasing concentrations of siRNA, and observing which concentration 
resulted in the greatest decrease in protein expression of the SNX protein targeted by the siRNA, 
determined by immunoblot. Figure 4.3 presents the results of the SNX1 siRNA test; with Figure 4.3A 
presenting a representative immunoblot displaying increasing concentrations of SNX1 siRNA 
transfected into FRT-KCa3.1-BLAP cells, and Figure 4.3B exhibiting the quantification of the 
immunoblots from Figure 4.3A. The lanes run in figure 4.3A are all FRT-KCa3.1-BLAP cells, and are 
transfected as follows; lane 1 has no transfection, lane 2 was transfected with 40 pM control siRNA, 
and lanes 3-5 were transfected with 10, 20, or 40 pM SNX1 siRNA respectively. This preliminary 
knockdown of SNX1 proved non-significant up to the transfection with 40 pM of SNX1 siRNA, 
however, future transfections with 40 pM of SNX1 siRNA proved successful (section 4.4.3; figure 
4.9), suggesting these experiments failed due to either poor technique or poor transfection media 




The preliminary experiments suggested that the SNX1 siRNA would not lead to a significant 
decrease in the intracellular protein levels of SNX1 (Figure 4.3), and that the SNX27 siRNA 
would not lead to a significant decrease in the intracellular protein levels of SNX27. Figure 4.4 
presents the results of the SNX27 siRNA test; Figure 4.4A depicts a representative immunoblot 
with lysates from cells transfected with increasing concentrations of SNX27 siRNA, and Figure 
4.4B characterises the quantification of the immunoblots for SNX27, and Figure 4.4C illustrates 
the quantification for the immunoblots for KCa3.1. Figure 4.4B reveals that transfecting cells 
with 40 pM SNX27 siRNA lead to the largest decrease in SNX27 protein levels, however, there 
was no significant difference between any of these groups (p > 0.05; n=3).  
Figure 4.3 – siRNA optimisation for SNX1. This figure displays the results of optimising the siRNA for SNX1. A. 
Representative immunoblot for SNX1 siRNA optimisation. Lane 1 contains lysate from untransfected FRT-
KCa3.1-BLAP cells, Lane 2 reveals lysate from cells transfected with 40 pM control siRNA, and Lanes 3-5 contain 
lysate from cells transfected with 10, 20, or 40 pM SNX1 siRNA. B. Quantification of the SNX1 immunoblots. 
These results reveal no significant changes between the control siRNA and any of 10, 20, or 40 pM siRNA 
transfections on the amount of SNX1 in the cell (p > 0.1; n=3). ANOVA analysis was performed between each 




Figure 4.4 – siRNA optimisation for SNX27. This figure demonstrates the results of optimising the siRNA for 
SNX27. For this experiment, FRT-KCa3.1-BLAP cells were transfected with 10, 20, or 40 pM of SNX27 siRNA for 
48 hr. A. Representative immunoblot revealing the effect of increasing siRNA concentration on both SNX27 
expression, and KCa3.1 basolateral membrane population. Lane 1 displays lysate from untransfected FRT-
KCa3.1-BLAP cells, Lane 2 displays lysate from cells transfected with control siRNA, Lane 3 displays lysate from 
cells transfected with 10 pM SNX27 siRNA, Lane 4 displays lysate from cells transfected with 20 pM SNX27 
siRNA, and Lane 5 displays lysate from cells transfected with 40 pM SNX27 siRNA. B. Quantification of the 
SNX27 immunoblots. This quantification confers that transfecting cells with 40 pM SNX27 siRNA did not lead to 
a significant change in the intracellular levels of SNX27 (p > 0.05; n=3). C. Quantification of the KCa3.1 
immunoblots, demonstrating that transfecting cells with 40 pM SNX27 siRNA does not lead to a significant 
difference in the basolateral membrane  population of KCa3.1 (p > 0.05; n=3). ANOVA analyses were 
performed between each group in B and C to assess significance.  
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4.4 The effect of specific Sorting Nexin proteins on KCa3.1 trafficking to the 
basolateral membrane 
4.4.1 The effect of SNX4 on the trafficking of KCa3.1 to the basolateral 
membrane 
SNX4 is a sorting nexin which transports vesicles by interacting with the (-) end of dynein, 
allowing for the long range transport of cargo proteins (Traer et al., 2007). It has also been 
hypothesised that the tubules created by SNX4 may be used to traffic proteins lacking a specific 
sorting sequence, as they can be trafficked by bulk flow (Traer et al., 2007). For this section, SNX4 is 
presented first as results are presented in chronological order, allowing for changes in methodology 
to be more easily followed. In order to determine any effect SNX4 plays on the trafficking of KCa3.1 
to the basolateral membrane in polarised epithelial cells, several experiments were required. 
Figure 4.5 – Effect of SNX4 knockdown on the basolateral membrane population of KCa3.1. A. 
Representative  blot demonstrating intracellular SNX4 levels and membrane KCa3.1 populations in cells 
transfected with SNX4 siRNA. Lane 1 contains lysate from untransfected FRT-KCa3.1-BLAP cells, Lane 2 exhibits 
lysate from cells transfected with control siRNA, Lane 3 presents lysate from cells transfected with 40 pM SNX4 
siRNA, with the apical membrane population of KCa3.1 labelled, and Lane 4 displays lysate from cells 
transfected with 40 pM SNX4 siRNA, with the basolateral membrane population of KCa3.1 labelled. B. 
Quantification of the SNX4 immunoblots, UTR is untransfected, CTRL is control, SNX4 AL is SNX4 knockdown 
with apical KCa3.1 labelled, and SNX4 BL is SNX4 knockdown with basolateral KCa3.1 labelled. This data 
revealed that transfecting cells with 40 pM SNX4 siRNA leads to a ~70% decrease in SNX4 protein levels 
compared to cells transfected with 40 pM control siRNA (p < 0.001; n=5). C. Quantification of KCa3.1 
immunoblots. This data reported that transfecting cells with 40 pM of SNX4 siRNA did not lead to any 
significant difference in either the apical or the basolateral membrane populations of KCa3.1 (p > 0.1; n=5). 
ANOVA analyses were performed between each group in B and C to assess significance. 
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Primarily, it was necessary to ensure that a 40 pM transfection with SNX4 siRNA lead to a significant 
decrease in the intracellular levels of SNX4. It was unnecessary to conduct preliminary experiments 
regarding the detection of SNX4, or the transfection of SNX4 siRNA into FRT-KCa3.1-BLAP cells, as 
SNX4 was both found to be present, and knocked down in FRT cells by the McDonald Lab 
(McDonald, Unpublished Data). The effect of SNX4 on the basolateral membrane population of 
KCa3.1 was determined by immunoblot, where four samples were analysed; lysate from 
untransfected cells, lysate from cells transfected with 40 pM control siRNA, and the final two 
samples of lysate transfected with 40 pM SNX4 siRNA (Figure 4.5). It was demonstrated that 
transfecting cells with 40 pM of SNX4 siRNA lead to a ~70% decrease in the protein levels of SNX4 
compared to the control siRNA (p < 0.001; n=5) (Figure 4.5B). Both the untransfected cells and the 
control cells had the basolateral membrane population of KCa3.1 labelled, as did one of the samples 
transfected with 40 pM SNX4 siRNA. The other sample transfected with SNX4 siRNA had the apical 
membrane population of KCa3.1 labelled. This allowed for samples where SNX4 knockdown had 
been determined to occur to be re-run in order to determine if a subsequent change in the 
basolateral membrane population of KCa3.1 occurred, and if any KCa3.1 was missorted to the apical 
membrane (Figure 4.5). These results revealed no significant difference in the basolateral membrane 
population of KCa3.1 compared to the control (p > 0.0.5; n=5) (Figure 4.5C). The apical labelling of 
KCa3.1 seen here could be due to two factors; KCa3.1 is sorted to the apical membrane, or the 
epithelial monolayer was not completely formed during the apical labelling, leading to basolateral 
KCa3.1 being labelled as part of the “apical” labelling. Despite a significant knockdown of SNX4, 
there was no significant change in the basolateral membrane population of KCa3.1.  
Next, electrophysiology was used to determine any functional changes in KCa3.1 caused by 
SNX4 knockdown. For these experiments, both the 1-EBIO sensitive current and the clotrimazole 
sensitive current were measured across KCa3.1-BLAP FRT epithelia mounted in an Ussing chamber 
(Figure 4.6). The 1-EBIO sensitive and clotrimazole sensitive currents were defined by the vertical 
change in current (Δy) before and after the addition of either 1-EBIO or clotrimazole. These results 
displayed a significant decrease in the change in current seen when stimulating cells with 100 µM 1-
EBIO (1-EBIO sensitive current) in cells transfected with 40 pM SNX4 siRNA compared to cells 
transfected with 40 pM control siRNA (Figure 4.6B). While a significant (p < 0.05; n=5) change in the 
1-EBIO sensitive current was seen, there was no significant change seen in the current between cells 
transfected with 40 pM SNX4 siRNA and control cells when treated with 10 µM clotrimazole 
(clotrimazole sensitive current) (Figure 4.6C).. Finally, the transepithelial resistance was measured to 
ensure that a tight epithelia formed for each experiment. The transepithelial resistance at the time 
which 1-EBIO was taken, and the average resistance of both the control and knockdown traces were 
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compared and analysed. There were no significant differences found between any of the groups (p > 
0.05; n=5) (Figure 4.6D). The cells used for Ussing chamber experiments in figure 4.6 were paired 
with cells used for figure 4.5, meaning that all cells were passaged, seeded, and transfected at the 
Figure 4.6 – Effect of SNX4 knockdown on KCa3.1 function. A. Representative Ussing chamber traces 
presenting the effect of stimulating cells with both 100 µM 1-EBIO and inhibition by 10 µM clotrimazole, 
displaying FRT-KCa3.1-BLAP cells without siRNA transfection (Blue), cells transfected with 40 pM control siRNA 
(Red), and cells transfected with 40 pM SNX4 siRNA (Green). B. Quantification of 1-EBIO sensitive current, 
revealing a significant decrease in the 1-EBIO sensitive current in cells transfecteed with 40 pM SNX4 siRNA 
(SNX4) compared to the control (CTRL) (p < 0.05; n=5). There was no signficant difference seen between the 
untransfected cells (UTR) and the CRTL. C. Quantification of the clotrimazole sensitive current, conceding no 
significant differences between any of the groups measured (p > 0.1; n=5). D. Quantification of the 
transepithelial resistance for Ussing chamber experiments, showing no significant differences betweeen any of 




same time to ensure that if a decrease in SNX4 was seen in immunoblots, that same knockdown 
would be present in the cells used for electrophysiology.   
4.4.2 The effect of SNX27 on the trafficking of KCa3.1 to the basolateral 
membrane 
SNX27 is a unique sorting nexin, known to be involved in the trafficking of several proteins, 
including the tight junction protein ZO-2 (Zimmerman et al., 2013), and the basolaterally trafficked 
sodium hydrogen exchanger NHE3 (Singh et al., 2015). This trafficking of NHE3 suggests that SNX27 
may be able to traffic other basolaterally trafficked proteins, such as KCa3.1. The effect of SNX27 
was determined by transfecting cells with SNX27 siRNA, and measuring the intracellular protein 
levels of SNX27 and membrane bound KCa3.1 via immunoblot, and measuring membrane KCa3.1 
through Ussing chamber experiments. Figure 4.7A details the representative immunoblots for both 
SNX27 and KCa3.1, and the quantifications for these immunoblots are portrayed in Figure 4.7B and 
4.7C. Figure 4.7B reveals that transfecting cells with 40 pM SNX27 siRNA led to a significant decrease 
in the intracellular SNX27 expression compared to cells transfected with 40 pM control siRNA (p < 
0.01; n=4). Figure 4.7C however, features no significant differences between the control cells and 
the SNX27 knockdown cells for either the apical or the basolateral populations of KCa3.1. 
Additionally, there was no significant difference between the apical and basolateral membrane 
populations of KCa3.1 in cells transfected with 40 pM SNX27 siRNA. Interestingly, there was a trend 
towards a significant difference between the apical and basolateral membrane populations of 




As in the SNX4 experiments, Ussing chamber experiments were used to determine any 
functional changes in KCa3.1 caused by SNX27. Figure 4.8 displays the results of the Ussing chamber 
experiment conducted with cells paired to the cells used for the immunoblots in Figure 4.7. The 
Ussing chamber results demonstrate that there is a significant decrease in the effect of treating cells 
transfected with 40 pM SNX27 siRNA with 100 µM 1-EBIO compared to cells transfected with 40 pM 
Figure 4.7 – Effect of SNX27 knockdown on the basolateral membrane population of KCa3.1. A. 
Representative immunoblots displaying the SNX27 and KCa3.1 blots for SNX27 knockdown. Lanes 1 and 2 
contain lysate from cells transfected with 40 pM control siRNA, with lane 1 containing apically labelled KCa3.1, 
and lane 2 displaying basolaterally labelled KCa3.1 lysate. Lanes 3 and 4 represent cells transfected with 40 pM 
SNX27, with lane 3 displaying apically labelled KCa3.1, and lane 4 depicting basolaterally labelled KCa3.1. Both 
immunoblots contain lysates from the same cells, however were run on different gels. B. Quantification of the 
SNX27 immunoblots, revealing a significant decrease in the intracellular levels of SNX27 in cells transfected 
with 40 pM SNX27 siRNA (SNX27) compared to cells transfected with 40 pM control siRNA (CTRL) (p < 0.01; 
n=4). C. Quantification of the KCa3.1 immunoblots, presenting no significant difference between the CTRL and 
the SNX27 lysates, for either the apical membrane population of KCa3.1 (AL), or the basolateral membrane 
population of KCa3.1 (BL). Additionally, there was no significant difference between the AL and the BL in cells 
transfected with SNX27 siRNA, however there was a trend towards significance between the AL and the BL in 
the control cells (p < 0.1; n=4). A paired two sided t-tests was performed between the groups in B and an 
ANVOA analysis was performed in group C to assess significance.  
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control siRNA (p < 0.01; n=4). Contrary to this, there appears to be no significant difference in the 
Figure 4.8 – Effect of SNX27 knockdown on KCa3.1 function. A. Representative Ussing chamber trace 
presenting the effect of treating cells with both 100 µM 1-EBIO and 10 µM clotrimazole on cells transfected 
with 40 pM SNX27 siRNA (Red) compared to 40 pM control siRNA (Blue). B. Quantification of 1-EBIO sensitive 
current. This reveals that cells with significantly less SNX27 had a signfiicantly lower response to the addition 
of 1-EBIO compared to control cells (p < 0.01; n=4). C. Quantification of clotrimazole sensitive current, 
illustrating no signficaint difference in the clotrimazole sensitive response between the control cells or the 
SNX27 knock down cells (p > 0.1; n=4). D. Quantification of the transepithelial resistances showing no 
signficiant change in the transepithelial resistance in the cells transfected with SNX27 siRNA compared to the 
control cells (p > 0.1; n=4). Paired two sided t-tests were performed between each group in B, C, and D to 
assess significance.  
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relative function of KCa3.1 in FRT-KCa3.1-BLAP cells transfected with 40 pM control siRNA and 40 
pM SNX27 siRNA when treated with 10 µM clotrimazole. Additionally, the reduction in SNX27 did 
not appear to affect the transepithelial resistance (p > 0.1; n=4), revealing that the cells with 
decreased SNX27 were still able to form a functional, polarised epithelia (Figure 4.8D). 
4.4.3 The effect of SNX1 on the trafficking of KCa3.1 to the basolateral 
membrane 
The sorting nexin SNX1 is one of the primary sorting nexin proteins involved in the cargo 
selection into the cargo retention complex (Wassmer et al., 2007), along with SNX2, 5, and 6. In 
addition to the PX domain expressed by all SNX proteins, SNX1 contains a BAR domain, which aids in 
the creation of endosome tubulation vesicles. While there is currently no evidence that KCa3.1 is 
recruited into the Retromer pathway, a relationship between SNX1 and KCa3.1 could strongly 
suggest the possibility for KCa3.1 recycling by Retromer. The effect of SNX1 on the trafficking of 
KCa3.1 to the basolateral membrane was inspected, again through the use of siRNA. Similar to the 
SNX4 and SNX27 experiments examining KCa3.1, FRT-KCa3.1-BLAP cells were transfected with either 
40 pM of control siRNA or SNX1 siRNA. Figure 4.9A displays the representative immunoblot for both 
KCa3.1 and SNX1, along with the loading control GAPDH. From each of the SNX1 immunoblots, the 
average of the two control lanes (one with apical KCa3.1 labelled with streptavidin, one with 
basolateral labelled KCa3.1), and the average of the two SNX1 knockdown lanes was taken, and the 
averages were used to calculate the average knockdown seen across all immunoblots, presented in 
figure 4.9B. These results outlined a ~55% decrease in SNX1 protein expression in cells transfected 
with 40 pM SNX1 siRNA compared to the control cells (p < 0.05; n=4). From the KCa3.1 immunoblots, 
each lane was normalised to the control lane which contained the apical membrane population of 
KCa3.1 (CTRL AL). Figure 4.9C revealed that there were no significant differences between the 
control and the knockdown lanes, for either the apical or the basolateral membrane populations of 
KCa3.1. Additionally, there were no significant differences between the apical and basolateral 
membrane populations for either the control cells, or the cells transfected with 40 pM SNX1 siRNA.  
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Aside from immunoblot experiments, electrophysiology experiments to measure channel 
functionality were performed. These electrophysiology experiments were in the form of Ussing 
chamber experiments, and were utilised in order to determine any functional changes on KCa3.1 
caused by changed in intracellular SNX1. The representative trace for these Ussing chamber 
experiments is exhibited in Figure 4.10A. These traces boast a significantly reduced (~60%, p < 0.05; 
n=4) 1-EBIO sensitive current in cells transfected with 40 pM SNX1 siRNA compared to control cells, 
however, this decrease was not matched in the clotrimazole sensitive current (p > 0.1; n=4). As the 
decrease in the 1-EBIO sensitive current was not matched in the clotrimazole sensitive current, 
therefore it is unlikely that SNX1 plays a functional role in KCa3.1 trafficking. Additionally, as no 
significant change was observed in the basolateral membrane population of KCa3.1 in cells with 
decreased SNX1, it is unlikely that SNX1 portrays a role in the trafficking of KCa3.1 in polarised 
epithelial cells. Furthermore, the traces showed no significant change in the transepithelial 
Figure 4.9 – Effect of SNX1 knockdown on the basolateral membrane population of KCa3.1. A. 
Representative blots for SNX1 and KCa3.1. Lanes 1 and 2 display lysate from cells transfected with 40 pM 
control siRNA, while Lanes 3 and 4 demonstrate lysate from cells transfected with 40 pM SNX1 siRNA. Lanes 1 
and 3 represent lysate from cells with apical membrane located KCa3.1, and Lanes 2 and 4 display lysate from 
cells with the basolateral membrane. B. Quantification of the SNX1 immunoblots, revealing a significant 
decrease in the protein levels of SNX1 in cells transfected with 40 pM SNX1 siRNA compared to control cells (p 
< 0.05; n=4). C. Quantification of KCa3.1 immunoblots, demonstrating no significant differences between the 
control (CTRL) and SNX1 knockdown (SNX1) cells, for either the apical membrane population of KCa3.1 (AL), or 
the basolateral membrane population of KCa3.1 (BL). Additionally, there was no significant differences found 
between the CTRL AL and BL, or between the SNX1 AL and BL. Paired two sided t-tests were performed 
between the groups in B and an ANOVA analysis was performed in group C to assess significance.  
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resistance when cells were transfected with SNX1 siRNA (p > 0.1; n=4) (Figure 4.10D). As with the 
previous experiments, the resistance was measured at the point 1-EBIO was added. These results 
verify that the FRT-KCa3.1-BLAP cells formed a polarised monolayer effectively regardless of SNX1 




Figure 4.10 – Effect of SNX1 knockdown on KCa3.1 function. A. Representative trace displaying the effect of 
100 µM 1-EBIO and 10 µM clotrimazole on cells transfected with either 40 pM control siRNA or 40 pM SNX1 
siRNA. B. Quantification of the 1-EBIO sensitive current, revealing that transfecting cells with 40 pM SNX1 
siRNA lead to a significant reduction in the 1-EBIO sensitive current compared to cells transfected with 40 pM 
SNX1 siRNA (p < 0.05; n=4). C. Quantification of the clotrimazole sensitive current. These results demonstrate 
no significant differences in the clotrimazole sensitive current between the control cells and the SNX1 
knockdown cells. D. Quantification of the transepithelial resistance showing no significant change in the 
transepithelail resistance between the control and SNX1 knockdown cells (p > 0.1; n=4). Paired two sided t-
tests were performed between each group in B, C, and D to assess significance.  
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4.5 Summary of Results 
This project found that transfection of FRT-KCa3.1-BLAP cells with 40 pM of SNX(𝑥) (where 
(𝑥) = SNX1, SNX4, or SNX27) siRNA lead to a significant decrease in the intracellular levels of SNX(𝑥) 
respectively, as measured by immunoblot. In contrast to this, there was no significant difference 
found in the basolateral membrane population of KCa3.1 in FRT-KCa3.1-BLAP cells that were 
transfected with 40 pM of either SNX(𝑥) siRNA. There was no significant difference in the apical 
membrane population of KCa3.1 in the FRT-KCa3.1-BLAP cells transfected with 40 pM of SNX1 or 
SNX27 siRNA. I hypothesise that there would be no significant change in the apical membrane 
population of KCa3.1 in FRT-KCa3.1-BLAP cells transfected with 40 pM of SNX4 siRNA, however this 
was not measured due to time constraints. In electrophysiology experiments, treating cells with 100 
µM of the KCa3.1 stimulator 1-EBIO showed a significant decrease in current in FRT-KCa3.1-BLAP 
cells transfected with 40 pM of either SNX(𝑥) siRNA when compared with control cells. In contrast, 
treating cells with 10 µM of the KCa3.1 inhibitor clotrimazole showed no significant change in the 
current in FRT-KCa3.1-BLAP cells transfected with either SNX(𝑥) siRNA when compared to control 
cells.  
Finally, a plasmid containing KCa3.1-HA-pcDNA3.1 was extracted from E.coli. A restriction 
digest was performed to ensure that the extracted plasmid contained the correct genetic 
information. When the plasmid was incubated with the restriction enzymes EcoR1 and Xho1, the 
plasmid split into two portions of the appropriate sizes to be KCa3.1-HA and the remaining plasmid. 
A transfection experiment was then carried out to determine the optimal transfection time and 
concentration for KCa3.1-HA expression. 1 or 2 µg of KCa3.1-HA-pcDNA3.1 was transfected into COS-
7 cells for either 24 or 48 hours, however the results proved inconclusive, and the experiment was 




5 Discussion  
5.1 Preface 
The intermediate conductance calcium-activated potassium channel, KCa3.1, is a channel 
expressed throughout the body, where it plays a variety of roles. Amongst these are; an active role 
in both smooth muscle (Neylon et al., 1999) and fibroblast proliferation (Neylon et al., 1999; Wang 
et al., 2013a), which can affect cardiac fibrosis (Wang et al., 2013a; Zhao et al., 2015). Additional 
roles of KCa3.1 include fluid secretion, resulting in dysfunction of KCa3.1 being fully or partly 
responsible for the phenotypes of diseases such as hereditary xerocytosis (Andolfo et al., 2013; 
Glogowska et al., 2015; Rapetti-Mauss et al., 2015) and sickle cell anaemia (Lew & Bookchin, 2005), a 
role in ulcerative colitis (Al-Hazza et al., 2012), and a role in at least two renal diseases; autosomal 
polycystic kidney disease (Yoder et al., 2002), and diabetic nephropathy (Qi et al., 2006; Grgic et al., 
2009). KCa3.1 has also been portrayed as a potential therapeutic target in several cancers, such as 
gliomas (Abdullaev et al., 2010), lung cancers (Bulk et al., 2015), hepatocellular carcinomas (Liu et 
al., 2015), and renal clear cell carcinomas (Rabjerg et al., 2015). Moreover the use of the 
pharmacological KCa3.1 inhibitor Senicapoc, has been studied as a therapy for both hereditary 
xerocytosis (Rapetti-Mauss et al., 2016), and in sickle cell anaemia (Ataga et al., 2008), suggesting 
that KCa3.1 can be targeted safely to reduce the pathophysiological symptoms of disease.  
The diversity of tissues in which KCa3.1 can be found, along with the still growing list of 
pathological conditions, has created a need to discover the mechanisms surrounding both KCa3.1 
trafficking to and from the plasma membrane. As previously discussed in the introduction, little is 
known about KCa3.1 trafficking, although both the Devor (University of Pittsburgh) and Hamilton 
(University of Otago) laboratories have made substantial advancements in this area. Two separate 
Rab proteins, Rab1 and Rab8, are known to be involved in the anterograde trafficking of KCa3.1 
(Bertuccio et al., 2014). Rab1 is responsible for trafficking of proteins from the ER to the cis-Golgi 
body (Zhang et al., 2009), while Rab8 is responsible for trafficking from the trans-Golgi body to the 
plasma membrane (Dong et al., 2010). KCa3.1 was also shown to not traffic through either RME-1 or 
transferrin receptor positive recycling endosomes, which suggest direct trafficking from the Golgi 
body to the basolateral membrane in polarised epithelial cells (Bertuccio et al., 2014). Recently, both 
the cytoskeleton and the motor protein myocin-Vc also have been implicated in the trafficking of 
KCa3.1 (Farquhar et al., 2017). The inhibition of either the cytoskeleton or of myocin-Vc leads to a 
significant decrease in the basolateral membrane population of KCa3.1. Additionally, both myocin-Vc 
and the cytoskeletal elements are known to interact with Rab8 (Chabrillat et al., 2005; Watanabe et 
al., 2008; Xu et al., 2009). This led Farquhar and colleagues to suggest that myocin-Vc simply allows 
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KCa3.1 to travel along the microtubule cytoskeleton to the basolateral membrane, rather than 
directly trafficking KCa3.1 to the basolateral membrane (Farquhar et al., 2017).  
An area of cellular physiology which has gained traction recently is the Retromer pathway that 
is involved in both the recycling and degradation of plasma membrane protein (Arighi et al., 2004; 
Chen et al., 2010; Temkin et al., 2011), and helps to regulate endosome to trans-Golgi body (Arighi et 
al., 2004). This pathway consists of multiple protein complexes, namely the cargo recognition 
complex (CRC), consisting of VPS26, VPS29, and VPS35 (Norwood et al., 2011), and the Wiskott-
Aldrich syndrome protein and SCAR Homologue (WASH) complex (Derivery et al., 2009; Gomez et 
al., 2012). The protein complexes involved in Retromer interact with each other, and interact with 
multiple individual proteins, such as sorting nexin (SNX) proteins (Wassmer et al., 2009).  
While Retromer is involved in the recycling of proteins such as the basolaterally located β2 
adrenergic receptor (β2AR), which is recycled by SNX27 directly to the plasma membrane from the 
early endosome (Lauffer et al., 2010; Temkin et al., 2011), KCa3.1 has been shown to not traffic 
through the recycling endosome (Lin et al., 2012). However, there is some evidence that KCa3.1 may 
be recycled. Schwab and colleagues found that KCa3.1 was subject to clathrin mediated endocytosis 
in migratory cells, and discovered that KCa3.1 appeared to be residing in the plasma membrane for 
longer than expected, a finding which Schwab and co-workers believe is consistent with the notion 
of channel recycling (Schwab et al., 2012). Furthermore, another member of the KCNN gene family, 
KCa2.3, is recycled in polarised both endothelial and epithelial cells (Gao et al., 2010; Lin et al., 
2012). This recycling has been shown to be partially dependent on an amino acid sequence within 
the N-terminus. While this 12 amino acid sequence (GQPLQLFSPSNP (Gao et al., 2010)) is not 
conserved in KCa3.1, there is a possibility of a recycling domain on KCa3.1, as some groups believe 
that KCa3.1 can be recycled in certain cell types (Schwab et al., 2012).  
In order to study the effect of the Retromer on KCa3.1 recycling in epithelia, in this project the 
SNX proteins SNX1, SNX4, and SNX27 were studied. FRT-KCa3.1-BLAP cells were transfected with 40 
pM of either control siRNA or SNX(𝑥) (where (𝑥) = SNX1, SNX4, or SNX27) siRNA in order to 
decrease intracellular expression of a specific SNX protein. The effectiveness of this knockdown was 
then measured by immunoblot, as was the membrane populations of KCa3.1, and the quantified 
results were normalised and compared to the cells transfected with 40 pM control siRNA. 
Furthermore, KCa3.1 function at the basolateral membrane was measured through Ussing chamber 
experiments, where the change in current was measured after stimulating or inhibiting the KCa3.1 
channel, and differences in the change in current between the control and knockdown cells were 
analysed. I hypothesised that transfecting FRT-KCa3.1-BLAP cells with SNX(𝑥) siRNA would lead to a 
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significant decrease in the intracellular expression of that SNX protein. Additionally, I hypothesised 
that this significant decrease in the SNX protein levels would lead to a significant decrease in the 
basolateral membrane population of KCa3.1, as measured by immunoblot, and a significant decrease 
in both the 1-EBIO and clotrimazole sensitive currents, compared to control epithelia.   
5.2 Technical approach 
For this project, a robust, reliable KCa3.1 labelling system was required, as accurate 
determination of the membrane population of KCa3.1 was vital to observe the channel at the 
basolateral membrane. The labelling system used in this study was based on the internal 
biotinylation method developed by Alice Ting (Chen et al., 2005), and modified to biotinylate KCa3.1 
by Devor and colleagues (Balut et al., 2010). This method of internal biotinylation centres around 
cells stably transfected with KCa3.1 which has been modified to contain a biotin ligase acceptor 
peptide (BLAP) sequence on an extracellular loop between the 3rd and 4th transmembrane domains. 
The plasmid these cells were transfected with also contains a biotin ligase enzyme (BirA), modified 
to contain an endoplasmic reticulum retention motif (BirA-KDEL) (Figure 3.2). In the cell, this system 
allows for KCa3.1 to be synthesised in the ER by ribosomes, then subsequently biotinylated by BirA 
on the BLAP sequence. At the plasma membrane, KCa3.1 functions normally, whilst exhibiting an 
extracellular biotin, which can be detected by selective labelling with streptavidin, allowing for 
immunoblots where only membrane bound KCa3.1 is shown. Gao and colleagues compared KCa3.1 
to KCa3.1-BLAP, and found that the addition of BLAP did not significantly affect the activation of 
KCa3.1 by DCEBIO, nor the inhibition of KCa3.1 by clotrimazole (Gao et al., 2010). Moreover, it has 
been published that neither KCa3.1 trafficking nor function is adversely affected by the addition of 
the BLAP sequence (Gao et al., 2010).  
This plasmid was stably transfected into Fischer Rat Thyroid (FRT) cells, which are able to form 
a polarised epithelial sheet (Winter et al., 2011). The resultant cell line in known as FRT-KCa3.1-BLAP 
cells. As FRT-KCa3.1-BLAP cells retain the ability to form polarised epithelial sheets, the cells were 
cultured onto semi-permeable membranes for experimental procedures, allowing for both the apical 
and basolateral membrane populations of KCa3.1 to be independently observed.  
5.3 Experimental overview 
This study was undertaken with four experimental goals to be competed. The base aspect of 
this project was the preliminary experiments; the sidedness experiment, where the basolateral 
localisation of KCa3.1 was confirmed (Figure 4.1), the SNX antibody tests, where antibodies 
confirmed that each SNX protein was present in FRT cells (Figure 4.2), and the SNX siRNA tests, 
where the ability of each SNX siRNA to decrease the corresponding protein was determined (Figures 
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4.3 and 4.4). The sidedness experiment served to ensure that KCa3.1 was being trafficked to the 
basolateral membrane, as reported in previous studies (Bertuccio et al., 2014; Farquhar et al., 2017). 
The SNX antibody tests ensure that the antibodies were able to detect endogenously expressed SNX 
proteins in FRT cells. Finally, the SNX siRNA tests served to find the optimal concentration of siRNA 
to transfect into cells.  
The second area of this project was to ensure that transfecting cells with 40 pM of SNX(𝑥) 
siRNA led to a significant decrease in SNX(𝑥) protein expression compared to cells transfected with 
40 pM control siRNA. If a passage of cells were found to have no decrease in the SNX(𝑥) intracellular 
protein levels, the neither the apical nor the basolateral membrane populations of KCa3.1 were 
measured. Changes in the relative intracellular protein levels of SNX(𝑥) were measured through 
immunoblot experiments.  
The third part of this project observed the membrane populations of KCa3.1 in cells 
transfected with 40 pM SNX(𝑥) siRNA or control siRNA. For cells transfected with 40 pM SNX(𝑥) 
siRNA, the apical and basolateral membrane populations of KCa3.1 were independently measured, 
and were compared to the membrane population of KCa3.1 in cells transfected with 40 pM control 
siRNA. As previously mentioned, these experiments were only carried out on cells with a decrease in 
intracellular SNX(𝑥) protein expression due to transfection of cells with SNX(𝑥) siRNA.  
The final aspect of this project was to observe the functional expression of KCa3.1 in FRT-
KCa3.1-BLAP cells transfected with 40 pM SNX(𝑥) siRNA, then measuring the relative change in 
current, as determined by Ussing chamber experiments. The change in current was measured 
following the addition of either 1-EBIO or clotrimazole, in order to detect the 1-EBIO sensitive 
current or the clotrimazole sensitive current in both epithelia transfected with 40 pM control siRNA 
and cells transfected with 40 pM SNX(𝑥) siRNA. The differences in both the 1-EBIO sensitive current, 
and the clotrimazole sensitive current were measured in both the control epithelia and the SNX(𝑥) 
knockdown epithelia.  
While four aspects of this project have been outlined, the final three were carried out 
simultaneously, and in parallel. Cells for these experiments were all seeded from the same passage 
of cells, and transfected with 40 pM of siRNA. Additionally, all the cells were cultured in the same 
environment, eliminating many variables which may reduce consistency. This allowed for the 
assumption that the Ussing chamber experiments experienced the same SNX(𝑥) knockdown as the 
immunoblot experiments, where the level of knockdown was easily measured. It was imperative 
that the SNX(𝑥) knockdown was identical in the Ussing chamber experiments, as it allowed for 
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changes in current seen when the KCa3.1 at the cell membrane was simulated with 1-EBIO or 
inhibited with clotrimazole to be matched to a % decrease in the intracellular SNX(𝑥) protein levels.  
5.3.1 Preliminary experiments 
As mentioned above, the preliminary experiments for this project consisted of the sidedness 
experiment, the antibody tests, and the siRNA tests. The sidedness experiment (Figure 4.1) revealed 
that the majority of KCa3.1 was expressed at the basolateral membrane compared to both the cells 
where no membrane bound KCa3.1-BLAP channels were not labelled through the use of streptavidin 
(hereafter referred to as unlabelled cells) (p < 0.05; n=4), and to apically labelled cells (cells where 
the apical membrane population of KCa3.1 was labelled with streptavidin) (p < 0.05; n=4). While the 
difference between the apical and basolateral membrane populations of KCa3.1 was not significant, 
there was a trend towards significance seen, suggesting that significance may emerge with more 
experiments. Previous studies have shown that KCa3.1 is located solely in the basolateral membrane 
(Bertuccio et al., 2014; Farquhar et al., 2017). This suggests the possibility that the small, non-
significant amount of KCa3.1 detected at the apical membrane compared to the negative control 
was due to streptavidin. If the cellular monolayer was not fully confluent when streptavidin was 
placed on the apical membrane, some of the basolaterally located KCa3.1 may have been 
accidentally labelled. Alternatively, if not all the streptavidin was removed by washing steps, then 
streptavidin on the apical membrane could bind to the basolaterally located KCa3.1 during cell lysis. 
As there was a trend towards a significant difference seen between the apical and basolateral 
membranes in the sidedness experiment, this difference was considered to be the baseline for other 
experiments. Ergo, apical expression akin to what was seen in Figure 4.1 was considered to be 
normal, and siRNA experiments with only a small amount of apical expression were not considered 
to be caused by KCa3.1 missorting to the apical membrane. Furthermore, later in this project, the 
apical expression of KCa3.1 was measured in both the control and knockdown cells. This allowed for 
relative changes in the apical KCa3.1 signal to be measured, ensuring that any perceived apical 
missorting of KC3.1 in cells where Retromer was disrupted was actually occurring.  
The antibody test (Figure 4.2) for this project proved two things. Firstly, these results revealed 
that both the anti-SNX1 and the anti-SNX27 antibody indeed identified endogenously expressed 
proteins in FRT cells, as protein bands appeared in the lysate from FRT cells. Secondly, these results 
demonstrated that both SNX1 and SNX27 were present in FRT cells, as the protein bands occurred at 
the correct molecular weight. These protein bands appeared in both the positive control lysate 
(lysate from HEK293 cells, as shown by immunoblot provided by the manufacturer) and in the lysate 
from FRT cells.  
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The SNX27 siRNA test (Figure 4.4) for this project determined the optimal siRNA concentration 
for transfecting cells with SNX27 siRNA, showing that transfecting cells with 40 pM SNX27 siRNA led 
to the largest decrease in SNX27 protein levels compared to the cells transfected with 40 pM of 
control siRNA, however this was not a significant change (p > 0.05; n=3).  
Additionally, the antibody used to detected the C-terminus of SNX27, and suggested that 
SNX27 run at 28 kDa, rather than 61 kDa. The antibody purchased for detection of SNX27 stated that 
SNX27 run at 28 kDa, however, after the preliminary experiments, it was revealed that other SNX27 
antibodies detected SNX27 at 61 kDa. My preliminary experiments were not able to detect SNX27 at 
60 kDa, as the PVDF membrane was sectioned horizontally with reference to the protein ladder to 
allow for simultaneous detection of both SNX27 (28 kDa) and GAPDH (37 kDa). This meant that any 
higher molecular weight bands of SNX27 were located on the GAPDH portion of the membrane. 
SNX27 was detected at 61 kDa by a member of the McDonald Lab. This allowed for the accurate 
detection of the whole SNX27 protein at 61 kDa using the antibody available, rather than detecting a 
portion of the SNX27 protein at 28 kDa, as detected in Figures 4.2 and 4.4. 
I believe that the detection of SNX27 at 28 kDa was insufficiently accurate for the preliminary 
experiments, ergo the more accurate detection at 61 kDa was required in order to determine a more 
accurately calculated knockdown of SNX27. When determining the effect of SNX27 on the 
basolateral membrane population of KCa3.1, it was vital to accurately determine if a transfection 
with SNX27 siRNA was successful, as any experiments where a siRNA transfection did not elicit a 
significant decrease in the protein levels were not accepted to measure changes in the membrane 
populations of KCa3.1. 
 On the other hand, the SNX1 siRNA test (Figure 4.3) for this project did not show any 
significant decrease in SNX1 expression in any of the SNX1 siRNA transfections, up to 40 pM. There 
are a number of possibilities as to why these transfections did not yield a significant decrease in the 
intracellular expression of SNX1, including unrefined transfection technique, bad transfection 
reagents or media, or non-specific protein binding for SNX1. Figure 4.3 showed the representative 
immunoblot for SNX1, and also shows a faint band underneath the perceived SNX1 band, suggesting 
the possibility of nonspecific protein bands being detected by anti-SNX1 in FRT cells. This non-
specific binding did not occur in the SNX1 experiments discussed in section 5.3.4.   
5.3.2 The effect of SNX4 on the trafficking of KCa3.1 
The first sorting nexin protein whose effect I studied on the trafficking of KCa3.1 was SNX4; a 
protein involved in the trafficking of vesicles from the early endosome to the trans-Golgi body and 
back to the plasma membrane (Traer et al., 2007). Silencing of SNX4 expression results in the 
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transferrin receptor being sent into the lysosomal degradation pathway, rather than being recycled 
(Traer et al., 2007). If decreasing the protein levels of SNX4 indeed affects the membrane population 
of KCa3.1, it could suggest that KCa3.1 is recycled by a previously unknown mechanism. Therefore, it 
is important to examine the possibility that SNX4 plays a role in the trafficking of KCa3.1.  
Before any effect of SNX4 on the trafficking or membrane population of KCa3.1 could be 
established, a significant decrease in the intracellular expression of SNX4 had to be observed. FRT-
KCa3.1-BLAP cells were seeded onto semipermeable filters, then were transfected with 40 pM of 
either control siRNA or SNX4 siRNA. This transfection resulted in a 62 ± 12% decrease in the 
intracellular protein levels of SNX4 compared to the control, which was highly significant (Figure 
4.5B) (p < 0.001; n=5).  
When immunoblots detected that a successful SNX4 siRNA transfection occurred, a second 
sample of this cellular lysate was run on immunoblot in order to measure the apical and basolateral 
membrane populations of KCa3.1. This was possible as both the apical and basolateral membrane 
populations of KCa3.1 were labelled prior to cell lysis. It was hypothesised that, by decreasing the 
intracellular protein levels of SNX4, the basolateral membrane population of KCa3.1 would also be 
reduced. As both the apical and the basolateral membrane populations of KCa3.1 were measured in 
cells transfected with SNX4 siRNA, any KCa3.1 missorted from the basolateral to the apical 
membrane would be able to be detected. Figure 4.5C shows no significant change in the basolateral 
membrane population of KCa3.1 between the control cells and the cells transfected with SNX4 
siRNA. Interestingly, there was also no significant difference between the basolateral membrane 
population of KCa3.1 in the control cells and the apical membrane population of KCa3.1 in the SNX4 
knockdown cells (Figure 4.5C). This could suggest that some KCa3.1 was missorted from the 
basolateral membrane to the apical membrane, however, it is possible that the FRT-KCa3.1-BLAP 
cells did not completely cover the filter they were grown on. This could have led to some of the 
basolateral membrane population of KCa3.1 to be labelled in the apically labelled samples. 
Additionally, this experiment highlighted the need to measure the apical membrane population of 
KCa3.1 in the cells transfected with 40 pM control siRNA. The apical membrane population of KCa3.1 
was not measured in the control cells for this experiment as previous experiments have shown the 
basolateral localisation of KCa3.1 (Bertuccio et al., 2014; Farquhar et al., 2017). Following this 
experiment, the apical membrane population of KCa3.1 was labelled in order to allow for changes in 
not only the basolateral membrane population of KCa3.1 to be measured, but for changes in the 
apical membrane population of KCa3.1 to be measured as well.  
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The final aspect of detecting any effect which SNX4 plays on the trafficking and membrane 
populations of KCa3.1 was performing Ussing chamber experiments. This was performed by seeding 
and transfecting cells at the same time and with the same concentrations of siRNA as the 
immunoblot experiments discussed above, to ensure that any changes detected were indeed due to 
a change in SNX4. Additionally, both the 1-EBIO and the clotrimazole sensitive currents were 
measured, to ensure that any changes seen in the current were truly due to changes in the 
membrane population of KCa3.1, and not due to contaminating factors, such as other potassium 
channels, which may be activated by 1-EBIO (Bahia et al., 2005). It was shown that, in cells 
transfected with 40 pM SNX4 siRNA, there was a significant 36 ± 8% decrease in the 1-EBIO 
stimulated current than in control cells (Figure 4.6B) (p < 0.05; n=5). In contrast to this, cells 
transfected with 40 pM SNX4 siRNA did not show any significant difference in the clotrimazole 
sensitive current compared to the control cells (Figure 4.6C) (p > 0.1; n=5). As the change in the 1-
EBIO sensitive current was not consistent with the clotrimazole sensitive current, nor by the 
immunoblot experiments, it is likely that the basolateral membrane population of KCa3.1 is not 
affected by SNX4. It is may be possible that the change in the 1-EBIO sensitive current is due to the 
presence of another EBIO-sensitive K+ channel, for example, an SK channel, which are also 
stimulated by the presence of 1-EBIO (Pedarzani et al., 2001), although no reports could be found of 
SK channels present in FRT cells. On the other hand, clotrimazole does not appear to inhibit SK 
channels (Malik-Hall et al., 2000). It is known that the SK3 (KCa2.3) channel is recycled in endothelial 
cells (Lin et al., 2012), although KCa3.1 was revealed to not be recycled in endothelial cells. However, 
it is may be possible that KCa3.1 is recycled in FRT cells, as KCa3.1 is closely related to KCa2.3, as 
both channels are from the KCNN gene family. KCa3.1 was hypothesised to be recycled in migratory 
cells (Schwab, 2012), which may further increase the possibility of KCa3.1 recycling in FRT cells.  
Finally, it was determined that there was no change in the transepithelial resistance when 
cells were transfected with SNX4 siRNA (p > 0.05; n=5) (Figure 4.6D). This strongly suggests that the 
FRT-KCa3.1-BLAP cells used for this experiment were able to form a confluent tight epithelial 
monolayer when SNX4 was knocked down. This is important as a tight epithelia is vital for the 
success of Ussing chamber experiments.  
I hypothesised that decreasing the intracellular protein levels of SNX4 would decrease the 
basolateral membrane population of KCa3.1, as measured by both immunoblots and Ussing 
chamber experiments. Immunoblot experiments showed no significant decrease in the basolateral 
membrane population of KCa3.1 in cells with less SNX4. Additionally, the Ussing chamber 
experiments did not show a significant decrease in the basolateral membrane population of KCa3.1. 
These results prove that my hypotheses were incorrect, and strongly suggest that SNX4 does not 
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appear to play a role in the trafficking of KCa3.1. Furthermore, it appears that KCa3.1 is not 
trafficked by bulk flow along the tubules formed by SNX4, as the basolateral membrane population 
of KCa3.1 did not significantly change when SNX4 was knocked down. Certain proteins, such as TfnR, 
are trafficked through SNX4 tubules while not directly interacting with SNX4 itself, instead being 
sorted into these tubules in a geometrical manner (Cohen & Pintavirooj, 2004). These results suggest 
that, unlike TfnR, KCa3.1 is not indirectly sorted by SNX4, nor directly interacts with SNX4 to be 
trafficked between the plasma membrane and the early endosome. While it appears that KCa3.1 
trafficking in unaffected by SNX4, it is possible that other SNX proteins with similar roles, such as 
SNX1/2, which are also involved in cargo selection and trafficking (Wassmer et al., 2009). 
Additionally, as SNX1 and SNX4 both form sorting tubules in the early endosome, it is possible that 
KCa3.1 is not trafficked by SNX proteins in order to reach the early endosome for its degradatory 
pathway (Carlton et al., 2004; Traer et al., 2007). The effect of SNX1 on the trafficking of KCa3.1 is 
further discussed in section 5.3.4.  
5.3.3 The effect of SNX27 on the trafficking of KCa3.1 
SNX27 is a unique sorting nexin protein, containing a PDZ domain, a domain unseen amongst 
other SNX proteins. SNX27 has been shown to aid in trafficking the β2AR (Lauffer et al., 2010), and 
the sodium-hydrogen exchanger NHE3, which is trafficked to the basolateral membrane (Singh et 
al., 2015). SNX27 utilises both its FERM domain and its PDZ domain in order to selectively traffic its 
cargo (Lauffer et al., 2010; Temkin et al., 2011; Steinberg et al., 2013; Gallon et al., 2014). 
Additionally, in SNX27 depleted cells, it was shown that cargo was sent into a lysosomal 
degradation pathway (Lee et al., 2016).  
As with the effect of SNX4, the effect of SNX27 on KCa3.1 trafficking and basolateral 
membrane population could not be examined before a SNX27 knockdown was observed. FRT-
KCa3.1-BLAP cells were transfected with either 40 pM control siRNA or 40 pM SNX27 siRNA, and 
the cellular lysates were run on an immunoblot. These results showed a 27 ± 4% decrease in the 
intracellular levels of SNX27 compared to the control cells (Figure 4.7B) (p < 0.01; n=4). While this 
knockdown appeared smaller than the SNX27 knockdown (51 ± 10% decrease) seen in the SNX27 
siRNA test (p > 0.05)(Figure 4.4), this knockdown was significant, unlike the SNX27 knockdown of 
the siRNA test. It is possible that this difference in the transfections was because the original 
immunoblots detected SNX27 at 28 kDa, as per the manufacturer’s instructions, rather than 
detecting the protein at 61 kDa, the size of SNX27 published by other groups. When SNX27 was 
detected at 61 kDa in FRT-KCa3.1-BLAP cells transfected with 40 pM of SNX27 siRNA, using the 
same antibody, a significant decrease in the intracellular levels of SNX27 was observed (p < 0.01; 
n=4) (Figure 4.7B).  
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Just as with looking at the effect of SNX4 on the membrane population of KCa3.1, the 
cellular transfections where a decrease in the intracellular protein levels of SNX27 was observed 
were used to observe the apical and basolateral membrane populations of KCa3.1. Unlike with the 
SNX4 experiments, these immunoblots studied both the apical and basolateral membrane 
populations of KCa3.1 in the control cells as well as in the SNX27 siRNA transfected cells. This 
allowed for any differences in the apical membrane population of KCa3.1 to be measured, rather 
than making the assumption that no KCa3.1 would be detected at the apical membrane of control 
cells. When the immunoblots were analysed, there was no significant difference detected in the 
basolateral membrane population of KCa3.1 between the control cells (CTRL BL) and the cells 
where a SNX27 knockdown was performed (SNX27 BL) (Figure 4.7C). This suggested that SNX27 
was not involved in the trafficking of KCa3.1 to the basolateral membrane.  
Interestingly, the apical membrane population of KCa3.1 in the cells transfected with 40 pM 
SNX27 siRNA appeared to be higher than the apical population of KCa3.1 in the control cells, with 
what was approaching significance (Figure 4.7) (p = 0.0818; n=4). As these results are from only 4 
experiments, this could suggest that without SNX27, the basolaterally targeted KCa3.1 is missorted 
to the apical membrane. However more experiments would be required before any conclusions 
could be drawn. If the apical membrane population of KCa3.1 is indeed increased when SNX27 is 
decreased, but the basolateral membrane population is decreased, it could suggest that surplus 
KCa3.1 is produced under normal conditions, and there is a cellular process to limit the basolateral 
membrane population of KCa3.1, however the apical membrane is free to be occupied.  
 Additionally, the basolateral membrane population of KCa3.1 in the control cells was almost 
significantly higher than the apical membrane population of KCa3.1 in the control cells (Figure 
4.7C) (p < 0.1; n=4), which appears to suggest that the FRT-KCa3.1-BLAP cells seeded for this 
experiment formed a near confluent monolayer, with very little streptavidin leaking through to the 
basolateral membrane KCa3.1, although this is unconfirmed. The results seen in Figure 4.7C 
suggest that the SNX27 siRNA knockdown which caused a 27 ± 4% decrease in SNX27 was unable 
to significantly decrease the basolateral membrane population of KCa3.1, however a more 
substantial reduction in the intracellular protein expression of SNX27, or an increased number of 
experiments may have shown that KCa3.1 was able to be missorted to the apical membrane. This 
being said, no conclusions can be drawn from the immunoblots in Figure 4.7.  
Again, like with SNX4, the SNX27 immunoblot experiments were paired to Ussing chamber 
experiments. These results showed an 83 ± 8% decrease in the 1-EBIO sensitive current, which is 
highly significant (p < 0.001; n=4) (Figure 4.8B). While this decrease in current appears promising, it 
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is likely that this result is not solely due to changes in the membrane population of KCa3.1, as only 
a 27 ± 4% decrease in SNX27 was observed (Figure 4.7B). As with SNX4, this amplified 1-EBIO 
sensitive current may be the result of other SK channels, which are stimulated by 1-EBIO alongside 
KCa3.1 (Pedarzani et al., 2001) however, the presence of SK channels in FRT cells must first be 
confirmed by immunoblot, as there were no published reports of any SK channels present in FRT 
cells at the time of writing of this report. If SK channels, including KCa2.3, are present in FRT cells, 
and if a decrease in SNX27 leads to a decrease in basolateral membrane population of KCa2.3, this 
could aid in the magnitude of change seen, and this could be even more significant if KCa2.3 was 
missorted to the apical membrane. In order to test this hypothesis, it is vital to first observe 
endogenous KCa2.3 in FRT cells, a gap in the current literature. This is because the Ussing chamber 
set up for this experiment had an artificial K+ gradient designed to amplify the basolateral K+ 
current of KCa3.1, ergo if KCa3.1, or a similar channel, was missorted to the apical membrane, it 
would have an amplified negative effect on the 1-EBIO sensitive current. While an 83 ± 8% 
decrease in the 1-EBIO sensitive current was seen in cells transfected with 40 pM SNX27 siRNA 
compared to the control (Figure 4.8B), this decrease was not seen in the clotrimazole sensitive 
current. While there was a slight decrease seen in the clotrimazole sensitive current (27 ± 14%), 
this was not significant (p > 0.1; n=4) (Figure 4.8C). This further suggests that the 1-EBIO sensitive 
current seen is not solely due to changes in the basolateral membrane population of KCa3.1.  
Finally, there appeared to be no significant differences between the transepithelial 
resistance of the control cells and the SNX27 deficient cells (p > 0.1; n=4) (Figure 4.8D), 
demonstrating that the cells were able to form a tight epithelial monolayer with significantly 
decreased intracellular levels of SNX27 (Figure 4.8D). This is especially important in the case of 
SNX27, as SNX27 has been shown to traffic ZO-2 (Zimmerman, 2013), suggesting that cells with less 
SNX27 may not form tight junctions as efficiently, which may allow for the streptavidin used to 
label the apical population of KCa3.1 to leak through to the basolateral membrane more easily. If 
there was a significant decrease in the transepithelial resistance, it could signify that the increase 
in the apical membrane population of KCa3.1 was due to more streptavidin leaking through the 
transcellular pathway. As there is no significant change in the transepithelial resistance, it is 
possible that the almost significant increase in the apical membrane population of KCa3.1 in the 
SNX27 scarce cells is due to KCa3.1 being missorted to the apical membrane from the basolateral 
membrane, however more experiments are required to confirm this.  
For this aspect of the project, my first hypothesis was correct, and transfecting cells with 40 
pM SNX27 siRNA lead to a significant decrease in the intracellular levels of SNX27 (Figure 4.7B). My 
second hypothesis was not correct, as there was no significant change in the basolateral 
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membrane population of KCa3.1 in the SNX27 knockdown cells compared to the control cells 
(Figure 4.7C). However, it is possible that some KCa3.1 was missorted to the apical membrane 
without leading to a decrease in the basolateral membrane population of KCa3.1. Finally, my third 
hypothesis, that both the 1-EBIO sensitive current and the clotrimazole sensitive currents would be 
decreased in cells transfected with 40 pM SNX27 siRNA, was incorrect, as there was no significant 
change in the clotrimazole sensitive current, despite the change in the 1-EBIO sensitive current 
(Figure 4.8). These results suggest that KCa3.1 does not interact with SNX27. Additionally, it 
appears unlikely that the KCa3.1 channel is trafficked along SNX27 specific tubules. This is 
consistent with the current literature on KCa3.1, as SNX27 is involved in the recycling pathway 
from the early endosome to the plasma membrane, as shown in Figure 1.6 (Lauffer et al., 2010; 
Temkin et al., 2011; Gallon et al., 2014; Lee et al., 2016). Previously, it has been shown that KCa3.1 
is not recycled in endothelial cells, unlike the similar KCa channel, KCa2.3 (Lin et al., 2012). 
Additionally, KCa3.1 trafficking in epithelial cells is recycling endosome independent (Bertuccio et 
al., 2014), instead being trafficked directly to the basolateral membrane (Bertuccio et al., 2014). 
The results shown here suggest that KCa3.1 is not recycled in a SNX27 dependent mechanism, 
strengthening the hypothesis that KCa3.1 is not recycled in epithelial cells. The results seen here, 
and the results published by Lin and colleagues (2010), and Bertuccio and collaborators (2014), are 
not supported by the work of Schwab and contemporaries (2012), who suggest that KCa3.1 is 
recycled in migratory epithelial cells, however, do not provide evidence of a specific mechanism, 
instead stating that their observations were consistent with the notion of channel recycling, 
however noting the lack of channel internalisation kinetics data. This could suggest that KCa3.1 is 
trafficked differently in migratory cells compared to stationary cells.  
5.3.4 The effect of SNX1 on the trafficking of KCa3.1 
Finally, the effect of SNX1 on the trafficking of KCa3.1 was measured. In vivo SNX1 forms a 
dimer with either SNX5 or SNX6, as does the similar SNX2 (Griffin et al., 2005; Rojas et al., 2007; 
Wassmer et al., 2007). SNX1 contains a BAR domain, which aids in the formation of vesicles and the 
internalisation of membrane bound proteins (Peter et al., 2004; van Weering et al., 2012). 
Furthermore SNX1 has been shown to recycle the basolaterally trafficked protein E-cadherin (Bryant 
et al., 2007), suggesting that SNX1 is capable of recycling other basolaterally trafficked proteins.  
When FRT-KCa3.1-BLAP cells were transfected with 40 pM SNX1 siRNA, compared to cells 
transfected with 40 pM control siRNA, a significant decrease in the intracellular protein levels of 
SNX1 were detected (Figure 4.9B) (p < 0.05; n=4). This decrease in SNX1 is significantly more than 
was detected in the SNX1 siRNA test (p < 0.01) (Figure 4.3). The increased transfection efficiency 
seen in Figure 4.9 compared to Figure 4.3 is likely due to multiple factors, including; more refined 
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transfection technique due to months more practice, and the use of a different batch of transfection 
media. As each batch of transfection media is made by hand, small differences in the pH or 
concentration may occur, which could have upset the delicate balance needed for successful siRNA 
transfections.  
In the SNX1 knockdown cells where a decrease in SNX1 was detected were then used to 
observe the apical and basolateral membrane populations of KCa3.1 in both the control and the 
SNX1 depleted cells (Figure 4.9C). These results showed no significant difference in the basolateral 
membrane population of KCa3.1 in either the control cells or the cells where SNX1 was reduced. This 
suggests that SNX1 is not involved in the trafficking of KCa3.1 to the basolateral membrane. 
Similarly, there was no significance seen in the differences in the apical membrane population of 
KCa3.1 between the control cells and the cells transfected with SNX1 siRNA. As KCa3.1 is not 
expected in the apical membrane in control cells, this suggests that a reduction in SNX1 did not lead 
to missorting of KCa3.1 from the basolateral membrane to the apical membrane. Following the 
trend of non-significance, there was no significance seen between the apical or basolateral 
membrane populations of KCa3.1 in the cells transfected with either 40 pM control siRNA or 40 pM 
SNX1 siRNA, suggesting the possibility that the FRT-KCa3.1-BLAP cells did not completely form a 
monolayer on the filters used for immunoblot experiments, allowing for apical streptavidin to label 
the basolateral membrane population of KCa3.1. As mentioned previously, it is known that, in a 
confluent epithelial monolayer, KCa3.1 is localised to the basolateral membrane (Farquhar et al., 
2017).  
Just as with the SNX4 and SNX27 experiments, this experiment utilised functional experiments 
in the form of Ussing chamber experiments (Figure 4.10). These experiments showed a significant 
decrease in the 1-EBIO sensitive current in the cells transfected with 40 pM SNX1 siRNA compared to 
the cells transfected with 40 pM control siRNA (p < 0.05; n=4) (Figure 4.10B). This 61 ± 11% decrease 
in the 1-EBIO sensitive current was not matched by the clotrimazole sensitive current, which only 
has a 45 ± 19% decrease in the SNX1 knockdown cells compared to the control cells, a decrease 
which is statistically non-significant (p > 0.1; n=4) (Figure 4.10C). As the cells did not exhibit a change 
in the clotrimazole sensitive current, nor in the basolateral membrane population of KCa3.1 when 
transfected with SNX1 siRNA, it is highly unlikely that SNX1 is involved in the trafficking of KCa3.1. 
Additionally, there was no significant change in the transepithelial resistance when cells were 
transfected with SNX1 siRNA (p > 0.1; n=4) (Figure 4.10D). This signifies the formation of a tight 
epithelial monolayer in the cells with less SNX1. The formation of a tight epithelial monolayer proves 
that the Ussing chamber results are not due to a leakier or defective epithelia.  
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The results seen here strongly suggest that SNX1 is not involved in the trafficking of KCa3.1, 
either to or from the plasma membrane. Additionally, combined with the results presented in 
section 4.4.1, which examined the potential role of SNX4 in the trafficking of KCa3.1, it is unlikely 
that any SNX proteins are involved in the trafficking of KCa3.1 between the plasma membrane and 
the early endosome. This is suggested as both SNX1 and SNX4 are key proteins in the formation of 
SNX sorting tubules, and both branch from the plasma membrane to the early endosome for 
membrane protein transport (Carlton et al., 2004; Traer et al., 2007). As KCa3.1 does not appear to 
be internalised by a SNX1 specific mechanism, it is unlikely that KCa3.1 is transported from the 
endosome to trans-Golgi body, as SNX1 is one of the defining features of this pathway (Bujny et al., 
2007). Furthermore, it is unlikely that either SNX5 or SNX6 play a role in the trafficking of KCa3.1, as 
SNX1 possesses a well-documented interaction with both SNX5 and SNX6, with suppression of either 
SNX5 or SNX6 leading to a decrease in SNX1 expression (Wassmer et al., 2007). It is also unlikely that 
SNX2 portrays a role in the trafficking of KCa3.1, due to its similarity to SNX1, as these proteins are 
believed to have interchangeable roles in trafficking (Rojas et al., 2007), however, as SNX2 is similar 
to SNX1, it is possible that the effect of SNX1 knockdown is blunted by the upregulation of SNX2. 
Finally, it is improbable that SNX3 plays a role in the trafficking of KCa3.1, as SNX3 has been 
suggested to utilise the tubules created by SNX proteins such as SNX1 (Strochlic et al., 2007). This is 
because SNX3 is unable to synthesise their own transport structures (Strochlic et al., 2007).  
When the intracellular protein levels of either SNX1, SNX4, or SNX27 are reduced by siRNA 
transfection, a significant decrease in the 1-EBIO sensitive current was observed. This would suggest 
that the functional expression of KCa3.1 is reduced, however none of these transfections lead to a 
significant, or trended towards a significant decrease in the clotrimazole sensitive currents. This 
suggests that another factor was responsible for the change in the 1-EBIO sensitive current. I 
hypothesise that another member, or members of the KCNN gene family may be responsible for this, 
providing that this channel is endogenously expressed in the FRT cell line. As mentioned earlier, the 
small conductance calcium activated K+ channel KCa2.3 has been shown to be recycled in epithelial 
cells (Gao et al., 2010; Lin et al., 2012). 
5.4 Limitations 
In this project, there were several limitations, which were minimised where possible. Of these 
limitations, perhaps the most prevalent was that the KCa3.1 activator, 1-EBIO, is not completely 
specific to KCa3.1, instead also activating the KCa3.1 relatives, KCa2.1, KCa2.2, and KCa2.3 (Pedarzani 
et al., 2001), which appeared to cause a misleading change in the 1-EBIO sensitive current. While 
KCA2.3 is found in human thyroid tissue, a search of the NCBI Geo database revealed no evidence of 
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any of the KCa2.1, KCa2.2, or KCa2.3 channels being present in rat thyroid tissues. Additionally, no 
literature confirming either the presence or the absence of these channels in rat thyroid tissues was 
uncovered, therefore the presence of SK channels in rat thyroid tissue must be confirmed before this 
hypothesis can be examined. Another limitation for this project was streptavidin labelling KCa3.1-
BLAP at the basolateral membrane when put onto the apical membrane, due to an incomplete 
epithelial monolayer, leading to false detection of KCa3.1 at the apical membrane, as shown in 
Figure 4.1. This limiting factor was minimised in the SNX27 and SNX1 experiment by measuring the 
apical membrane population of KCa3.1 in both the control and the SNX diminished cells, however 
this was not controlled for in the SNX4 experiment, and time was not permitting for this to be 
repeated.  
Furthermore, it would have been prudent to reduce the amount of apical labelling of KCa3.1 in 
the sidedness experiments (Figure 4.1). This could have been completed in two ways. The first would 
have been to alter the original number of cells seeded onto the Transwell filters. By increasing the 
original number of cells onto the Transwell filter, cells will require less time to grow in order to form 
a confluent monolayer, ensuring that there were no gaps in the epithelial monolayer for streptavidin 
to move through. While this may have generated a confluent monolayer, seeding a higher number 
of cells may have reduced the cellular transfection efficiency as cells will have more surface area in 
contact with surrounding cells, ergo less contact with the surrounding media, which limits the ability 
of cells to take up the siRNA transfection. The second strategy would be similar to the first strategy; 
changing the cellular growth time. By increasing the time between seeding cells and cellular lysis, the 
cells will have more time to grow and ergo more likely to form a confluent monolayer. The final 
approach would be to use cells of a lower passage, as cells of a higher passage did not perform as 
well. However, by increasing growth time or initial seeding densities, the risk of overgrowing cells 
increases. FRT cells were observed forming domes by growing vertically once a confluent monolayer 
has been formed. The resulting cells may not be polarised, meaning that KCa3.1 is not localised to 
the basolateral membrane and would be able to be labelled at the apical membrane. 
Finally, a major limitation for this project was the deterioration of the currents seen in the 
control traces between experiments. This can best be seen between the control traces between 
figures 4.6A and 4.8A. It is unknown why there was such variation in the control current, as under 
ideal conditions, the control current would have been identical each time. In order to minimise the 
problems this may cause, during analysis, the knockdown current was normalised to the control, 
allowing for any changes to be seen more accurately. It is possible that using DCEBIO, a stronger 
KCa3.1 channel opener that 1-EBIO, would have resulted in greater changes in current, allowing for 
more accurate results to be obtained.  
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Aside from these specific limitations, there were also more general limitations, such as 
background fluorescence in the immunoblots and oxidation occurring in the electrodes used for the 
Ussing chamber. Background fluorescence was minimised by using smaller amounts of Lumilight 
solution, which made excess Lumilight easier to drain off by touching the edges of the PVDF 
membrane to a paper towel before fluorescence was detected. While this reduced the prevalence of 
excess background fluorescence, one had to be careful to ensure that the whole PVDF membrane 
was covered in Lumilight solution in order to ensure that the experiment was accurate. The 
oxidation seen on the electrodes of the Ussing chamber was minimised in two ways. The first way 
was to ensure that the agar used to plug the end of the electrode was fresh when new electrodes 
were made, so that it would form an effective plug. The second way was to create new electrodes 
regularly, as the agar plugs in the electrodes degraded over time and with use. This helped to 
prevent electrodes from oxidising in the middle of an experiment, leading to electrodes being 
required to be remade, and extra, unnecessary errors being present.  
Another limitation to this project was the use of only one cell line; Fischer rat thyroid cells. It is 
possible that results could vary if a different cell line was utilised, however due to time constraints, 
this was not possible. If time were not an issue, the use of multiple cell lines to confirm that findings 
were consistent would have been ideal. 
5.5 Future directions 
This study has left two main questions which need to be answered in order to completely 
understand the results gained. The first question is regarding the trend towards a significant increase 
in the apical membrane population of KCa3.1 in cells with less SNX27. As mentioned above, the 
possibility of KCa3.1 missorting to the apical membrane needs to be examined. This could be done in 
two parts; firstly using fluorescently tagged KCa3.1 to determine if any KCa3.1 is located in the apical 
membrane when SNX27 is diminished, and secondly performing immunoprecipitation experiments 
to determine if SNX27 and KCa3.1 interact. One problem experienced with this project regarding 
immunoprecipitation experiments was the inability to transfect cells with the KCa3.1-HA construct. I 
believe that this can be avoided by utilising the already available KCa3.1-BLAP present in FRT-KCa3.1-
BLAP cells. By lysing the cells prior to labelling the membrane bound KCa3.1 with streptavidin, then 
incubating the lysis in the streptavidin solution, the intracellular KCa3.1-BLAP would be labelled. This 
would allow for any intracellular interactions between KCa3.1 and the Retromer proteins to be 
detected, even if the interaction has ceased when KCa3.1 gets to the membrane. 
The second question I believe needs to be answered is regarding the increased change in 1-
EBIO sensitive current compared to the change in the clotrimazole sensitive current. As mentioned 
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above, it appears that transfecting cells with any of the three SNX siRNAs used for this project 
resulted in an unknown protein being decreased, which lead to a significant decrease in the 1-EBIO 
sensitive current. I believe a strong contender for this is the KCa2.3 channel, which is related to 
KCa3.1, and is opened by 1-EBIO (Pedarzani et al., 2001). KCa2.3 is present in human thyroid tissue 
(Fagerberg et al., 2014), suggesting that it would be present in FRT cells, however no data has been 
published regarding this. I believe it would be prudent to examine if KCa2.3, or either of the other 
two small conductance calcium activated potassium channels (KCa2.1 or KCa2.2), are present in FRT-
KCa3.1-BLAP cells. If any of these channels are present, it would be wise to inspect if the trafficking 
of these channels are affected by changes in retromer components, specifically the sorting nexin 
proteins used in this project.  
In future, I believe that it would be beneficial to perform immunoblots measuring the cell 
surface levels of the β2-AR as a positive control to confirm that the retromer pathway has been 
interrupted. The β2-AR was not used in this project due to time constraints surrounding the ability to 
measure cell surface β2-AR. Additionally, the McDonald laboratory had previously shown 
measurable changes in ENaC when components of the Retromer complex were knocked down. This 
suggested that, not only were the individual components of the Retromer pathway were knocked 
down, but that the overall trafficking pathway was being interrupted. 
Another experiment that I believe would be beneficial to perform in future is  to look at the 
effect of Senicapoc; a KCa3.1 channel inhibitor, on the effect of KCa3.1 trafficking. Senicapoc has 
been proposed as a potential treatment for Sickle Cell Anaemia (Ataga et al., 2008). I believe it 
would be interesting to investigate if treating cells with Senicapoc, combined with Retromer 
knockdowns, could have an effect on surface levels of KCa3.1. 
Aside from these experiments, which investigate the questions unanswered thus far by this 
project, I believe it would be beneficial to investigate several other factors. Primarily, it would be 
prudent to examine if decreasing the intracellular levels of multiple SNX proteins affects the 
basolateral membrane population of KCa3.1. Some Retromer proteins may be able to perform 
multiple roles if other proteins are knocked down, which would decrease any effects seen by 
knocking down that protein. In this project, SNX1 was knocked down, however, SNX2 plays a similar 
role to SNX1, and forms a complex with the same proteins as SNX1. Therefore, SNX2 may blunt the 
potential effects of knocking down SNX1. If both SNX1 and SNX2, or multiple other Retromer 
proteins were simultaneously knocked down, a change in the basolateral membrane population of 
KCa3.1 may emerge. However it would be important to follow these experiments with 
immunoprecipitation experiments. By immunoprecipitating KCa3.1 with the protein(s) knocked 
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down, it can be determined whether or not KCa3.1 has a direct interaction with these proteins, or if 
a detected change is due to a contaminating factor.  
5.6 Conclusion 
This project studied the effects of three sorting nexin proteins, SNX1, SNX4, and SNX27, on the 
membrane population of the intermediate conductance Ca2+ activated K+ channel. SNX1, SNX4, and 
SNX27 were selected for this project as each of these sorting nexins had unique functions, however, 
are all linked closely to the Retromer pathway. Primarily, this project was the first to reveal 
endogenous expression of both SNX1 and SNX27 in Fischer Rat Thyroid cells, and was the first to 
present that the intracellular protein levels of SNX1 and SNX27 could be reduced by transfecting 
these FRT cells with either SNX1 or SNX27 siRNA. In order to measure the changes in the basolateral 
membrane population of KCa3.1 when SNX1, SNX4, or SNX27 protein levels were decreased, both 
immunoblot and Ussing chamber experiments were utilised. This proved my first hypothesis, that 
SNX1, SNX4, and SNX27 would be knocked down when FRT-KCa3.1-BLAP cells were transfected with 
SNX1, SNX4, or SNX27 siRNA, to be correct.  
While my first hypothesis was correct, my second and third hypotheses; which stated that 
both the basolateral membrane population of KCa3.1 (second hypothesis) and the functionality of 
KCa3.1 as determined by the 1-EBIO and clotrimazole sensitive currents (third hypothesis) would be 
significantly reduced when one of SNX1, SNX4, or SNX27 were not proven correct. It was found that 
the basolateral membrane population of KCa3.1 was not significantly changed when cells were 
transfected with any of SNX1, SNX4, or SNX27 siRNA.   
When the intracellular protein levels of either SNX1, SNX4, or SNX27 were reduced by siRNA 
transfection, a significant decrease in the 1-EBIO sensitive current was observed. This would suggest 
that the functional expression of KCa3.1 is reduced, however none of these transfections lead to a 
significant, or trended towards a significant decrease in the clotrimazole sensitive currents. This 
suggests that another factor was responsible for the change in the 1-EBIO sensitive current. I 
hypothesise that another member, or members of the KCNN gene family may be responsible for 
this. As mentioned earlier, the small conductance calcium activated K+ channel KCa2.3 has been 
shown to be recycled in epithelial cells (Gao et al., 2010; Lin et al., 2012). These results are 
consistent with previous results suggesting the KCa3.1 is not recycled in nonmigratory cells (Gao et 
al., 2010; Lin et al., 2012). Additionally, these results suggest that none of SNX1, SNX4, or SNX27 are 
involved in the anterograde trafficking of KCa3.1 to the basolateral membrane. 
As it appears that neither SNX1, SNX4, nor SNX27 are involved in the trafficking of KCa3.1 to 
the basolateral membrane, some specific trafficking routes seem less likely to be utilised by KCa3.1. 
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Both SNX1 and SNX4 form unique sorting tubules (Traer et al., 2007), which transport proteins to 
specific locations. As the basolateral membrane population of KCa3.1 did not significantly change 
when either SNX1 or SNX4 were downregulated, it is unlikely that KCa3.1 is trafficked by either the 
SNX1 or SNX4 sorting tubules. Furthermore, the possibility of KCa3.1 being transported through a 
sorting tubule by bulk flow through a SNX4 sorting tubule is also unlikely, as there would be fewer 
tubules when SNX4 was downregulated (Cohen & Pintavirooj, 2004). While there is no evidence that 
SNX27 forms sorting tubules, it appears unlikely that KCa3.1 is trafficked by either SNX27 or Fam21. 
Lee and collaborators (2016) found that SNX27 and Fam21 form a close interaction. In systems 
where the SNX27/Fam21 dimer are trafficking cargo, the cargo is sent along the lysosomal 
degradation pathway when SNX27 is removed (Lee et al., 2016). As there was no significant change 
in the basolateral membrane population of KCa3.1 when the intracellular levels of SNX27 were 
reduced, it is unlikely that Fam21 is involved in the trafficking of KCa3.1.  
While these results appear conclusive, I believe that more research must be conducted on two 
areas; the effect of SNX27 on KCa3.1 missorting to the apical membrane, and determining the 
reason why downregulating each of SNX1, SNX4, and SNX27 lead to a significant decrease in the 1-
EBIO sensitive current but not in the clotrimazole sensitive current. If SNX27 is indeed responsible, 
or partially responsible for the basolateral localisation of KCa3.1, then SNX27 could increase the 
number of therapeutic targets for diseases involving KCa3.1 dysfunction. Due to the prevalence of 
KCa3.1 in several disease states (Section 1.4.4), it is vital to understand exactly how KCa3.1 is 
trafficked both to and from the plasma membrane. By understanding exactly how KCa3.1 is 
trafficked to the plasma membrane, the number of channels present in the plasma membrane can 
be more accurately controlled in cells. Additionally, by knowing how KCa3.1 is trafficked from the 
plasma membrane, it may become apparent that KCa3.1 can be “rescued” from degradatory 
pathways, and recycled to the plasma membrane. Alternatively, understanding how KCa3.1 is 
trafficked from the plasma membrane may lead to therapies revolving around increasing how long 
KCa3.1 can remain in the plasma membrane.  
As these results suggest that the Retromer pathway is not involved in the trafficking of KCa3.1 
to the basolateral membrane, this project is inconsequential for clinical situations involving KCa3.1. 
Furthermore, as the Retromer pathway is still largely not understood, any therapeutic remedies 
involving Retromer must be intensively studied to ensure that no unforeseen trafficking side effects 
occur. In the search for novel medicines to treat diseases caused by KCa3.1, other trafficking routes 
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